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Abstract 
We show that activation of Wnt/ȕ-catenin and attenuation of Bmp signals, by 
combined gain- and loss-of-function mutations of ȕ-catenin and Bmpr1a, respectively, 
results in rapidly growing, aggressive squamous cell carcinomas (SCC) in the salivary 
glands of mice. Tumors contain transplantable and hyper-proliferative tumor 
propagating cells, which can be enriched by FACS. Single mutations stimulate stem 
cells, but tumors are not formed. We show that ȕ-catenin, CBP and Mll promote self-
renewal and H3K4 tri-methylation in tumor propagating cells. Blocking ȕ-catenin-
CBP interaction with the small molecule ICG-001 and siRNAs against β-catenin, 
CBP or Mll abrogate hyper-proliferation and H3K4 tri-methylation, and induce 
differentiation of cultured tumor propagating cells into acini-like structures. ICG-001 
decreases H3K4me3 at promoters of stem cell-associated genes in vitro and reduces 
tumor growth in vivo. Remarkably, high Wnt/ȕ-catenin and low Bmp signaling also 
characterize human salivary gland SCC and head and neck SCC in general. Our work 
defines mechanisms by which β-catenin signals remodel chromatin and control 
induction and maintenance of tumor propagating cells. Further, it supports new 
strategies for the therapy of solid tumors.   
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Introduction 
Tumor propagating cells or cancer stem cells exhibit stem cell- or progenitor-like 
properties, i.e. they are able to either self-renew or to differentiate into multiple cell 
types (Barker et al, 2009; Ben-Porath et al, 2008; Sneddon & Werb, 2007). 
Understanding molecular mechanisms that regulate tumor propagating cells may help 
to develop rational therapies. Canonical Wnt signaling maintains many embryonic 
and adult stem cell types; this signaling system also contributes to the generation of 
tumor propagating cells (Clevers, 2006; Grigoryan et al, 2008; Malanchi et al, 2008; 
Wend et al, 2010). Conversely, Bmp signaling inhibits the tumorigenic potential of 
cancer stem cells of the brain (Piccirillo et al, 2006).  
 
Wnt/ȕ-catenin signals control transcription and gene expression through Wnt response 
elements (WRE) that are recognized by the ȕ-catenin-LEF/TCF complex, and 
modulate chromatin structure (Behrens et al, 1996; Molenaar et al, 1996; Mosimann 
et al, 2009). Hallmarks of chromatin states are modifications on the tails of core 
histones:  tri-methylation of lysines 4, 9 and 27 of histone H3 (H3K4me3, H3K9me3 
and H3K27me3) are associated with active chromatin, heterochromatin, and repressed 
chromatin, respectively (Albert & Peters, 2009; Goldberg et al, 2007). Various 
chromatin modifiers are recruited to the C-terminus of ȕ-catenin (Mosimann et al, 
2009). In Drosophila, β-catenin recruits CBP; the histone acetyltransferase (HAT) 
activity of CBP acetylates chromatin over wide regions surrounding particular WRE 
(Parker et al, 2008). ȕ-Catenin also interacts with histone methyltransferase MLL that 
promotes H3K4 tri-methylation (Sierra et al, 2006).  
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The developing salivary glands of human and mice are complex secretory organs, 
which in mice begin to develop from a simple epithelial bud around embryonic day 
(E)11.5-12.5 (Tucker, 2007). The mature glands include luminal ductal, acinar and 
intercalated duct cells that intermingle with stem cells, which express CD24 and 
CD29 surface markers (Hisatomi et al, 2004; Nanduri et al, 2011). Salivary gland 
stem cells contribute to maintenance and regeneration of the adult salivary glands in 
rodents and can amend the function of irradiated salivary glands after stem cell 
transplantation (Lombaert et al, 2008; Man et al, 2001; Nanduri et al, 2011). 
Regeneration of mouse salivary glands was recently found to depend on Wnt/β-
catenin signals (Hai et al, 2010). 
 
Head and neck carcinomas in humans amount to 6% of all cancers (Stewart & 
Kleihues, 2003), the majority being squamous cell carcinomas (SCC). SCC may 
originate from epithelial stem or progenitor cells of the epidermis or the mucous 
membranes. Subpopulations of cells from human head and neck SCC with tumor 
propagating cell properties have recently been isolated, based on the markers CD44 
and ALDH (Clay et al, 2010; Prince et al, 2007). Salivary gland carcinomas constitute 
only a fraction of head and neck cancers, and 8% are SCC, which often arise in the 
glandula parotis (Speight & Barrett, 2002). Salivary gland SCC are aggressive, 
produce early lymphogenic metastases, and have a poor prognosis (Ying et al, 2006).  
 
This study demonstrates that high-grade salivary gland SCC and head and neck SCC 
in general rely on high Wnt/β-catenin and low Bmp signaling for proliferation and 
self-renewal. In SCC, tumor propagating cells depend on the β-catenin-CBP complex 
but also MLL for the generation of an open chromatin state and the induction of a 
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stem cell-associated gene signature. Knowing that specific Wnt/ȕ-catenin inhibition 
can revert the chromatin state and lead to differentiation and tumor remission in vivo 
provides a step to safely eradicate tumor propagating cells.   
 
 
Results 
Head and neck squamous cell carcinomas in humans and mice display high Wnt/ȕ-
catenin and attenuated Bmp signals 
18 human salivary gland SCC and 29 other head and neck cancer of the SCC subtype 
were examined for Wnt/β-catenin and Bmp signaling activity (Supplementary Table 
1). The majority of tumors exhibited nuclear β-catenin, a hallmark of high canonical 
Wnt signals (Behrens et al, 1996; Grigoryan et al, 2008), and were negative for 
nuclear p-Smad 1/5/8 (Whitman, 1998), indicating that Bmp signals were low (Fig. 
1A). Nuclear β-catenin accumulated at tumor fronts (arrows on the left) (Fodde & 
Brabletz, 2007), whereas nuclear p-Smad persisted in differentiated central areas 
(arrow in inset on the right). 75% of grade 3 salivary gland SCC (SG-SCC), the most 
aggressive cancers, displayed nuclear β-catenin and were negative for p-Smad, 
whereas only 25% of grade 2 tumors displayed these characteristics (Fig. 1B, upper 
left; tumor grading criteria were as defined in (Barnes et al, 2005)). Similarly, two 
thirds of grade 3 head and neck SCC (HN-SCC) showed high nuclear β-catenin and 
low p-Smad staining (Fig. 1B, upper right). Cells with nuclear β-catenin at the tumor 
fronts also co-expressed cytokeratin (CK)10, which is a marker for squamous cell 
carcinoma (Chu & Weiss, 2002) (Supplementary Figure 1A).  A subset of nuclear β-
catenin-positive cells from human SG-SCC and HN-SCC co-expressed the marker 
CD24 (Fig. 1A*,C, left; quantifications are shown in B, lower panels, percentages 
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refer to all tumor cells) (Monroe et al, 2011; Visvader & Lindeman, 2008) and the 
marker CD44, which is specific for tumor propagating cells in HN-SCC (Fig. 1C, 
right; quantifications for grade 2 and grade 3 tumors are depicted in yellow letters 
below insets) (Prince et al, 2007; Visvader & Lindeman, 2008).  
 
To gain mechanistic insights into the relevance of β-catenin and BMP signals in 
tumor formation of salivary gland SCC, we created a mouse model. Combined β-
catenin gain-of-function (β-catGOF) and Bmp receptor 1a loss-of-function 
(Bmpr1aLOF) mutations were introduced by Cre recombinase driven by the Keratin 14 
gene, referred to as double mutants (Harada et al, 1999; Huelsken et al, 2001; Mishina 
et al, 2002) (see breeding scheme in Supplementary Fig. 1F). K14-Cre activity was 
confirmed by using a LacZ indicator mouse line; recombination occurred in ductal 
cells of the salivary glands (Supplementary Fig. 1B-E,G). Aggressive tumors 
appeared rapidly in the salivary glands of the double mutants (Fig. 1D, a schematic 
view of the normal mouse salivary glands is provided on 
http://www.informatics.jax.org/cookbook/figures/figure45.shtml). Kaplan-Meier plots 
show that double mutants succumbed to tumors rapidly, dying between postnatal day 
(P)75 and P90 (Fig. 1E). After full necroscopy, a pathologist (C.L.) determined that 
these tumors exclusively arose from the submandibular salivary glands. The tumors 
were classified as SG-SCC by histopathological criteria, contained keratin pearls and 
expressed high levels of CK10 (Supplementary Fig. 2A, right, see also inset) (Barnes 
et al, 2005; Chu & Weiss, 2002). Moreover, consistent with the human tumors, mouse 
SG-SCC also showed high Wnt/ȕ-catenin and low Bmp signals, as determined by 
staining for β-catenin, the Wnt target gene Axin2 and pSmad1/5/8 (Supplementary 
Fig. 2B). Neither single β-catGOF nor Bmpr1aLOF mutant mice did develop tumors 
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(Fig. 1E, Supplementary Fig. 2A, middle panels). Gene expression profiling and gene 
set enrichment analysis at P1 and P90 revealed that in double mutant salivary glands, 
genes associated with proliferation as c-myc and differentiation/apoptosis as Loricrin 
or Fas were up-regulated and down-regulated, respectively, when compared to β-
catGOF tissues (Supplementary Fig. 2C, Supplementary Tables 2 and 3, see also 
below). Other K14-expressing tissues of double mutants did not develop tumors; 
while epithelia of the esophagus and forestomach showed no significant histological 
changes, we observed excessive supernumerary hair follicles in the skin, when 
compared to wildtype mice (Supplementary Fig. 2D). Taken together, the fast 
accumulation of salivary gland SCC in the double mutant mice was the net result of 
strong proliferation and reduced differentiation and apoptosis.   
 
Wnt/ȕ-catenin and Bmp signals control tumor propagating cells in salivary gland 
SCC 
In order to characterize cells that are specific and essential for tumor formation in 
double mutant salivary glands, we isolated CD24+CD29+ cells by fluorescence 
activated cell sorting (FACS) from glands of the different genotypes; these surface 
markers have been previously used to enrich for stem cells of salivary glands 
(Hisatomi et al, 2004; Nanduri et al, 2011; Visvader & Lindeman, 2008). The 
proportion of CD24+CD29+ cells increased 3-fold and 10-fold in single and double 
mutants, respectively, compared to controls (Fig. 2A, Supplementary Figure 3A-C). 
Enrichment of CD24+ cells could be confirmed by immunofluorescence analysis (Fig. 
2B). Isolated CD24+CD29+ cells were collected by cytospin and their proliferation 
was assessed using Ki67 antibody staining (Fig. 2C). CD24+CD29+ cells from double 
mutant salivary glands were hyper-proliferative: over 80% were Ki67+ (Fig. 2D), 
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compared to 13% non-sorted cells (Fig. 2E). High proliferation was confirmed by 
FACS for Ki67, which showed that over 90% of CD24+CD29+ cells were highly 
proliferating (P1 cells in Supplementary Fig. 4A,B). Another strongly proliferative 
CD24- subpopulation (up to 40% Ki67+) was identified, but these were not epithelial 
cells and instead expressed stromal markers (P4 cells, Supplementary Fig. 4A,B, and 
data not shown). The salivary gland tumors stained weakly for Sca-1 or c-kit (not 
shown) (Hisatomi et al, 2004), and the CD24+CD29+ subpopulation co-expressed the 
marker CD44 only at low levels (Supplementary Figure 3D,E). To examine the 
tumor-propagating potential, CD24+CD29+ cells of double mutants and various 
control cell populations were injected into the back skin of NOD/SCID mice (Fig. 2F) 
(Visvader & Lindeman, 2008). As few as 500 CD24+CD29+ cells from double mutant 
glands produced fast-growing tumors, while cells that expressed only high CD24 or 
CD29 did not produce fast-growing tumors (Fig. 2F,G, Supplementary Figure 4C). 
Unsorted cells from double mutant glands were only moderately tumorigenic, at 105 
but not 104 injected cells (Fig. 2F). Tumors arising from transplanted cells co-
expressed the SCC markers CK10 and CK14, and contained differentiated and 
undifferentiated areas (Supplementary Figure 4D,E). Transplanted tumors maintained 
stable subpopulations of CD24+CD29+ cells in serial transplantations that retained 
high tumor propagating potential (Supplementary Figure 4F,G). From these results, 
we conclude that CD24+CD29+ cells from double mutant salivary gland SCC are 
highly enriched for tumor propagating cells.  
 
Salivary gland tumor propagating cells are characterized by a stem cell-associated 
gene signature and specific chromatin marks 
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To elucidate mechanisms that potentiate the self-renewal of tumor propagating cells, 
we examined stem cell-associated genes that were co-expressed with activated Wnt/β-
catenin (Ben-Porath et al, 2008; Wend et al, 2010). Remarkably, tumor propagating 
cells of double mutants expressed embryonic-type SSEA1+ (Fig. 3A) (Read et al, 
,2009). The SSEA1 expression specifically characterized cells with high Wnt/β-
catenin signals since >90% of the CD24+CD29+SSEA1+ triple-sorted cells exhibited 
nuclear β-catenin, which was not found in other subpopulations (Fig. 3B, and data not 
shown). CD24+CD29+ cells were also characterized by low pSmad1/5/8 intensity, as 
compared to unsorted tumor cells (Supplementary Figure 5A,B). Gene expression 
profiling of CD24+CD29+ cells revealed that a number of genes associated with the 
pluripotent state were highly expressed (Supplementary Fig. 5C,D, Supplementary 
Table 4). Among those were Nr5a2, which can replace Oct4 in reprogramming of iPS 
cells (Heng et al, 2010), the ES-cell associated Snf2-like helicase Hells (Xi et al, 
2009), the stem cell marker Dppa5 (Ware et al, 2009) and the stem cell-associated 
chromatin modifiers Ash2, Mll (Dou et al, 2005) and Rnf2 (de Napoles et al, 2004). A 
GSEA analysis confirmed that genes important for pluripotent stages in organism 
development were enriched in double-mutant tumor propagating cells (Supplementary 
Table 3). Treatment for 24 hours with ICG-001, an inhibitor of canonical Wnt 
signaling that blocks β-catenin-CBP interaction (Emami et al, 2004), and siRNA-
mediated down-regulation of β-catenin significantly suppressed these genes (Fig. 3C).  
 
Previous research has shown that the maintenance of pluripotency is linked to the 
epigenetic state of cells (Albert & Peters, 2009; Surani et al, 2007; Wend et al, 2010). 
Remarkably, sorted CD24+CD29+ tumor propagating cells from double mutant 
salivary glands showed a marked increase of H3K4me3, as assessed by 
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immunohistological analysis of cytospins, which was low in CD24+CD29+ cells from 
wildtype and single mutant tissue (Fig. 3D, quantified in E). H3K4me3 generally 
characterizes transcriptionally active promoters, but high enrichment is also indicative 
of stem cell promoters (Albert & Peters, 2009; Gaspar-Maia et al, 2011; Wend et al, 
2010). In contrast, CD24+CD29+ cells from double mutants showed a low level of 
H3K27me3, compared to CD24+CD29+ cells from wildtype and single mutants (Fig. 
3D,E), whereas the H3K9me3 levels were similar in all genotypes (Fig. 3E, 
Supplementary Fig. 5E). These epigenetic marks in CD24+CD29+ cells from double 
mutants require high Wnt/β-catenin: after 24 hrs of ICG-001 treatment, the numbers 
of H3K4me3-positive cells declined by more than 60% (Fig. 3F). Similar changes in 
H3K4me3 and H3K27me3, but not H3K9me3, were also observed by Western blot 
analysis of extracts from salivary glands of control and mutant mice, and in tumors 
that arose from transplanted cells (Supplementary Fig. 5F). Thus, the specific 
alterations in chromatin-associated histone marks suggest that the overall epigenetic 
makeup has changed in the tumor propagating cells of the salivary glands. Further, 
tumor propagating cells are distinguished by the expression of a gene signature that is 
associated with pluripotency.  
 
To examine whether activated canonical Wnt signaling affects human salivary SCC in 
a similar manner, we assessed H3K4me3 and nuclear β-catenin levels in human 
tumors, which could be detected preferentially at the invasive tumor fronts 
(Supplementary Fig. 5G). We also investigated several tumor cell lines of human 
head and neck SCC. Endogenous Wnt signaling activity in these cells was variable, as 
assessed by the expression of the Wnt/β-catenin target gene Axin2 (Grigoryan et al, 
2008; Lustig et al, 2002). Typically, cell lines with high and low Wnt activity (e.g., 
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HN-SCCUM-03T and HN-SCCUM-02T) displayed opposite, i.e., low and high 
pSmad1/5/8 levels, respectively (Supplementary Fig. 6A). HNSCCUM-03T cells with 
high Wnt activity were treated with ICG-001, which down-regulated the expression of 
stem cell-associated signature genes NR5A2, ABCB1B, LRRC34, DNAJC6 and of the 
genes encoding chromatin modifiers HELLS, MLL and ASH2 (Supplementary Fig. 
6B). Conversely, CHIR 99021, a Wnt activator (Ring et al, 2003), up-regulated the 
expression of these genes in HNSCCUM-02T cells that display low endogenous Wnt 
signals (Supplementary Fig. 6B). Interestingly, a large number of HNSCCUM-03T 
cells with high Wnt co-expressed CD44, a stem cell marker of human SCC tumors, as 
well as CD24, whereas HNSCCUM-02T cells with low Wnt only co-expressed CD24 
and CD44 after Wnt activation, i.e., 48 hrs exposure to CHIR 99021 (Supplementary 
Fig. 6A,C) (Monroe et al, 2011). Collectively, mouse salivary gland and human head 
and neck SCC cells depend on high canonical Wnt signals to create a permissive 
epigenetic environment that allows the expression of a stem cell-associated gene 
signature. This includes the human-specific stem cell marker CD44 (Gires, 2011). 
 
ICG-001 treatment leads to tumor remission and reprograms salispheres to form 
differentiated acini-like structures  
CD24+CD29+ tumor propagating cells from the tumors of double mutant salivary 
glands were cultured. Remarkably, the canonical Wnt inhibitor ICG-001 strongly 
blocked proliferation of the CD24+CD29+ cells (Fig. 4A). We then performed a 
therapy experiment in NOD/SCID mice, which were transplanted with CD24+CD29+ 
tumor propagating cells that were forming tumors (see Fig. 2F): ICG-001 significantly 
reduced the size of the growing tumors (Fig. 4B).  
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Stem cells from organs and tumors can often be expanded as non-adherent, sphere-
like aggregates, which reflects their self-renewal capacity (Lombaert et al, 2008; 
Monroe et al, 2011; Visvader & Lindeman, 2008). Whereas CD24+CD29+ salivary 
gland cells from wildtype or single mutant mice did not grow as spheres, 
CD24+CD29+ cells from double mutants could be propagated as salispheres in the 
presence of hepatocyte growth factor, HGF (Fig. 4C, left panel) (Brinkmann et al, 
1995). In such salispheres, cells formed loose, net-like aggregates, i.e., displayed 
undifferentiated structures (Fig. 4D, left, see also below). Remarkably, in the presence 
of ICG-001, salispheres formed instead glandular structures that resemble salivary 
gland acini (Fig. 4C, second panel, Fig. 4D, right, the quantification of differentiation 
is in E). Light and electron microscopy demonstrated the formation of lumen, 
secretory granules and tight junctions in the acini-like structures but not in the 
undifferentiated salispheres (Supplementary Fig. 6E,F, and data not shown). ICG-001 
treatment also up-regulated the expression of the gene encoding Amylase 1, an 
enzyme of differentiated salivary glands (Supplementary Fig. 6G). Thus, 
CD24+CD29+ tumor propagating cells from salivary gland tumors of double mutant 
mice exhibit unrestricted self-renewal in salisphere culture that depends on canonical 
Wnt signaling. We next analyzed the effect of the HDAC inhibitor Valproic acid 
(VPA) and the DNA methylation inhibitor 5-azacytidine (Aza) (Ware et al, 2009) on 
ICG-001-elicited responses in salispheres. Inhibition of proliferation by ICG-001 was 
not seen in the presence of VPA or Aza, but differentiation was blocked (Fig. 4C, 
right panels, quantitation in Fig. 4E, Supplementary Fig. 6H). Furthermore, ICG-001 
treatment of human HNSCCUM-03T cells with high endogenous Wnt strongly 
reduced their ability to form spheres (Supplementary Fig. 6D). ICG-001 has been 
shown to inhibit the growth of Wnt/ȕ-catenin-dependent human tumor cells (Emami 
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et al, 2004; Wend et al, 2013). Conversely, CHIR 99021 enhanced the capacity of 
HNSCCUM-02T cells with low endogenous Wnt to form spheres (Supplementary 
Fig. 6D). Thus, unrestricted self-renewal of tumor propagating cells of mouse salivary 
glands and of human SCC tumor cell lines in sphere culture depends on continuous 
Wnt signaling and on the maintenance of their specific epigenetic state.  
 
Wnt/ȕ-catenin signals exploit MLL-dependent H3K4 histone methylation activity to 
establish and maintain salivary gland tumor propagating cells 
To learn about the significance of Wnt/β-catenin-dependent epigenetic regulation, we 
examined whether blocking ȕ-catenin-CBP by ICG-001 leads to changes of histone 
modifications at gene promoters of stem cell-associated genes. Chromatin 
immunoprecipitation (ChIP) using anti-H3K4me3 antibodies was performed with 
CD24+CD29+ cells from mouse salivary gland tumors and with human HNSCCUM-
03T tumor cells that display high Wnt activity. We detected high enrichments of 
H3K4me3 at sequences, which are in close proximity to the promoters of Mll, Hells, 
Ash2 and c-myc genes, but not at promoter-far sequences in the mouse and human 
cells (Fig. 5A,B). ICG-001 significantly decreased the enrichment of H3K4me3 at 
promoter-proximal sequences. We also examined the sequential order of changes in 
H3K4me3 and in gene expression of mouse CD24+CD29+ tumor propagating cells 
that depend on ICG-001. H3K4me3 down-regulation could be detected 12h after 
ICG-001 treatment (Fig. 5C). In contrast, expression changes of genes of the stem 
cell-associated gene signature or of the differentiation marker Amylase occur later, 
24h after ICG-001 treatment (Figure 5D). These data show that the β-catenin-CBP-
interfering substance ICG-001 elicits changes in H3K4me3 at target promoters, and 
that the epigenetic changes precede transcriptional changes.  
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We next addressed the question of how abrogation of Wnt/β-catenin signals might 
produce the shift of epigenetic marks. Remarkably, treating CD24+CD29+ cells from 
double mutant tumors with ICG-001 resulted in a significant translocation of β-
catenin out of the nucleus and in cytoplasmic accumulation (Fig. 6A, protein 
quantifications are shown above the blots). Concomitantly, Mll, a known binding 
partner of nuclear β-catenin with histone methyltransferase towards H3K4 (Sierra et 
al, 2006), disappeared from the nuclear fraction (Fig. 6B). Two protein products of 
the stem cell signature, Hells and Nr5a2, were also downregulated (Supplementary 
Fig. 7A). Conversely, activating Wnt/β-catenin with CHIR 99021 lead to an increase 
of nuclear ȕ-catenin and nuclear Mll (Figure 6A,B). The increase of β-catenin might 
be due to the product of the remaining wildtype allele in the double mutant mice (see 
Supplementary Figure 1F,G). Nuclear exclusion of β-catenin by inhibiting with ICG-
001 could also be detected in the human high Wnt HNSCCUM-03T cells 
(Supplementary Fig. 7B). Collectively, these data show that nuclear Mll and the 
expression of the stem cell-associated gene signature are dependent on the presence of 
high Wnt/ȕ-catenin signals.  
 
We next examined the potential role of Mll in the CD24+CD29+ cells of salivary 
gland tumors by performing siRNA-mediated down-regulation of β-catenin, CBP and 
Mll. These treatments resulted in a strong reduction of the numbers of H3K4me3+ and 
Ki67+ cells (Fig. 6C, Supplementary Fig. 7C). Down-regulation of another histone 
methyltransferase, Ash1, had no effect on H3K4me3 and Ki67 levels. ICG-treatment 
and siRNA against Mll or β-catenin also profoundly reduced the proliferation of 
tumor propagating cells, while siRNA against Dppa5 had no effect (Fig. 6D) (Kim et 
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al, 2005). Mll is strongly expressed in the tumor propagating cells of salivary glands; 
nuclear Mll was found to be associated with the rare CD24+ cells (Supplementary Fig. 
7E, arrows). Remarkably, knockdown of β-catenin and Mll by siRNA treatment 
resulted in acini formation in sphere culture, i.e., forced a large fraction of 
CD24+CD29+ cells into differentiation, whereas Ash1 siRNA had no effect (Fig. 6E). 
siRNA treatments did not affect all cells, in contrast to ICG-001, possibly due to 
incomplete transfection efficacy (Fig. 6C-E, Supplementary Fig. 7D). In order to 
show that ȕ-catenin and MLL are relevant in human salivary gland tumors, we 
evaluated the association of the gene products in the collection of 13 human SG-SCC 
specimens: nuclear ȕ-catenin was associated with nuclear MLL, and both products 
significantly correlated with high grade tumors (Fig 6F,G, Supplementary Fig. 7F,G; 
n=13). This may also lead to an up-regulation of other stem cell-associated genes, as 
exemplified for NR5A2 (Supplementary Fig. 7H). These data show that the 
association of nuclear ȕ-catenin with nuclear MLL is of clinical relevance in human 
SG-SCC. Collectively, our data suggest that in both, murine and human tumors, the β-
catenin/CBP/MLL axis drives self-renewal and fends off differentiation of tumor 
propagating cells via epigenetic mechanisms.  
 
 
Discussion 
Here we report that mice with increased Wnt/β-catenin and attenuated Bmp signaling 
in Keratin 14-expressing tissues rapidly develop salivary gland SCC, from which we 
can enrich tumor propagating cells by FACS. The importance of canonical Wnt 
signaling in tumor propagating cells is known (Barker et al, 2009; Malanchi et al, 
2008; Wend et al, 2010). We provide evidence that β-catenin activation leads to an 
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induction and stabilization of MLL, and that β-catenin, CBP and MLL are required to 
trigger H3K4 trimethylation at promoters of self-renewal genes in tumor propagating 
cells (Summary scheme in Fig. 7A). 
 
Tumor propagating cells from salivary gland SCC of double mutants were enriched 
by FACS using high expression of the CD24 and CD29 surface antigens as markers, 
and 500 of sorted cells produced tumors upon serial transplantation in immune-
compromised mice. Such serial transplantation experiments with low numbers of 
injected cells define tumor propagating cells, also called cancer stem cells (Gires, 
2011; Nanduri et al, 2011; Prince et al, 2007; Visvader & Lindeman, 2012). The 
tumor propagating cells of salivary gland SCC retained the capacity to differentiate 
following transplantation, akin to cancer stem cells (Visvader & Lindeman, 2008). In 
our hands, other markers and marker combinations failed to isolate cells that could be 
used to generate tumors at this low number of injected cells. We also compared the 
tumor propagating cells from the double mutants with CD24+CD29+ cells of wildtype 
and single mutant salivary glands; this revealed that proliferation was significantly 
higher in double mutant cells than in cells obtained from single mutants or control 
mice. Remarkably, 13% of the unsorted cells of tumors but 80-90% of the 
CD24+CD29+ cells were Ki67-positive in the double mutant tissue. In conclusion, 
constitutive activation of Wnt/β-catenin signals strongly increase self-renewal of 
tumor propagating cells, while repression of BMP signals inhibits apoptosis, which in 
combination leads to permanently hyper-proliferating salivary gland tumor cells. 
 
β-Catenin and CBP can tether MLL to promoters, where histone methyltransferase 
activity toward H3K4 is promoted (Arai et al, 2010; Dou et al, 2006; Emami et al, 
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2004; Mosimann et al, 2009; Taki et al, 1997). The trithorax-related MLL has been 
linked with gene activation and confers stem cell-like properties to hematopoietic 
cancer cells (Krivtsov & Armstrong, 2007; Schuettengruber et al, 2011; Visvader & 
Lindeman, 2008). Similarly, specific mutations of β-catenin bestow self-renewal 
properties to chronic myeloid leukemia cells (Jamieson et al, 2004). MLL can exist in 
high molecular weight complexes with other methyltransferase components such as 
ASH2, which can enhance the activity of the MLL core complex (Southall et al, 
2009). We found that high levels of nuclear β-catenin increase not only MLL, but also 
ASH2 levels in tumor propagating cells. Likewise, HELLS is up-regulated in a 
Wnt/β-catenin-dependent manner in CD24+CD29+ tumor propagating cells. It is 
noteworthy that MLL expression depends on HELLS in prostate cancers (von Eyss et 
al, 2011). This suggests that the expression of a network of chromatin-associated 
proteins might be amplified by a feed-forward mechanism, ensuring that β-catenin-
CBP-MLL has ample trithorax-related activity to maintain high H3K4me3 levels at 
target promoters. Further, differentiation of CD24+CD29+ tumor propagating cells is 
restored by down-regulation of canonical Wnt signaling, i.e., by ICG-001 or siRNA-
mediated down-regulation of β-catenin, CBP or MLL (scheme in Fig. 7B). The 
temporal coordination of epigenetic reshaping and target gene expression in the 
differentiation of salivary gland tumor propagating cells supports the hypothesis that 
the tumor cells depend on Wnt/β-catenin-MLL-mediated epigenetic changes to 
suppress salivary gland differentiation. Finally, ICG-001-mediated differentiation of 
CD24+CD29+ tumor propagating cells cannot occur in the presence of the HDAC-
inhibitor valproic acid or the DNA methylation inhibitor 5-azacytidine, indicating that 
chromatin remodeling is also critical for differentiation (scheme in Fig. 7B). 
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The strong effects of ICG-001 on tumor propagating cells might support new 
strategies for the development of rational therapies of solid tumors. Wnt/ȕ−catenin 
signaling inhibitors eliminated stem cells in non-solid tumors, and ICG-001 
eradicated drug-resistant leukemic cancer stem cells in vitro and in vivo (Takahashi-
Yanaga & Kahn, 2010). We show here that ICG-001 enforces differentiation of 
salivary gland tumor propagating cells in the mouse model, providing an efficient 
approach to target salivary gland cancer and potentially head and neck cancer in 
general. High Wnt/β-catenin and low Bmp signaling also correlate with the 
aggressiveness of human head and neck cancer and with the potential of the human 
tumor cells to self-renew. Moreover, the data with human cancers illustrate that 
nuclear ȕ-catenin is significantly correlated with nuclear MLL and high tumor grade. 
It will be important to test whether human head and neck cancers also respond to 
Wnt/β-catenin inhibitors.  
 
 
Materials and methods 
Mouse strains 
K14Cre(Δneo), β-cateninfloxEx3, Bmpr1aflox alleles and Cre-inducible lacZ reporter 
mice have been described, and mutant mice were analyzed for genotype and 
recombination by PCR (Harada et al, 1999; Huelsken et al, 2001; Mishina et al, 2002; 
Thorey et al, 1998). The conditional gain-of-function mutation of β-catenin was 
produced by crossing homozygous mice carrying the β-cateninlox(ex3) allele to K14-cre 
mice. The loss-of function mutation of Bmpr1a was produced by crossing 
homozygous mice carrying Bmpr1aflox alleles to K14-cre mice that were homozygous 
for the BmpRIAflox allele. To obtain the compound mutants, homozygous mice 
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carrying the β-cateninlox(ex3) gain-of-function and the BmpRIAflox loss-of-function 
allele  were crossed with K14-Cre mice that were homozygous for the Bmpr1aflox 
allele (a breeding scheme is shown in Supplementary Fig. 1F). Animal experiments 
were performed according to the EU and national institutional regulations.  
 
Immunodetection and other stainings 
Immunohistochemistry, immunofluorescence and H&E staining were performed on 
frozen or formalin-fixed paraffin-embedded tissue sections as described (Huelsken et 
al, 2001). Human tumor samples were obtained from the Institute of Pathology, 
Charité-UKBF Berlin, Germany, and from the Department of Otorhinolaryngology, 
University Hospital Düsseldorf, Düsseldorf, Germany (for patient data see 
Supplementary Table 1). Immunoblotting of Westerns was performed using standard 
protocols: cells were lysed in HNTG buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 
1% (w/v) Triton X-10, 10% (w/v) glycerol). Histone extraction was performed 
according to the technical instructions from Abcam. Protein lysates were subjected to 
SDS-PAGE and transferred to PVDF membranes. Membranes were incubated with 
specific antibodies, and Western blots were developed using the chemiluminescence 
method (PerkinElmer). The following primary antibodies were used for 
immunodetection: mouse-anti β-catenin (from BD Transduction Laboratories), rabbit-
anti phospho-Smad1/5/8, rabbit-anti cleaved caspase-3, mouse-anti CD44, rabbit-anti 
Axin2, rabbit-anti tri-methyl histone H3 (Lys4) (Cell Signaling), mouse-anti CK10 
and rabbit-anti CK14 (Covance), Phycoerythrin (PE)-conjugated rat-anti CD24 (BD 
Pharmingen), biotinylated goat-anti CD29 (R&D Systems), rabbit-anti phospho-
histone H3 (Upstate), rabbit-anti tri-methyl histone H3 (Lys9; Abcam), rabbit-anti tri-
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methyl histone H3 (Lys27) (Millipore), rabbit-anti MLL1 (Bethyl), rabbit-anti Lamin 
(Santa Cruz) and mouse-anti α-Tubulin (Sigma).  
 
Quantitative real-time PCR and microarray profiling 
Isolation of total RNA, cDNA synthesis and qRT PCR were performed using standard 
protocols: briefly, total RNA of tissue samples was isolated using Trizol (Invitrogen), 
and 5 ȝg total RNA was reverse-transcribed using MMLV reverse transcriptase 
(Promega) according to the instructions by the manufacturers. qRT PCR was 
performed using the iCycler IQTM 5 multicolor real-time detection system (Bio-Rad) 
with absolute SYBR green fluorescein (ABgene). PCR was carried out following a 
standard protocol: primer sequences used for qRT PCR can be found in Supplemental 
Table 5. Microarray profiling was performed using GeneChip Mouse Genome 430 2.0 
arrays (Affymetrix), following the protocol of the manufacturer. Profiling 
experiments are from salivary gland tissues of three mice in each group for the 
analysis at P1 and for the analysis of CD24+CD29+ stem cells at P90 (each n=3). 
Processing and statistical analysis of microarray data was performed using 
Genespring software.  
 
Bioinformatics and gene set enrichment analysis of gene expression data and mouse 
survival statistics 
Analysis of Affymetrix array data conformed to MIAME structure 
(http://www.mged.org). Log of ratio normalized expression data were analyzed using 
a cross-gene error model and normalized according to the manufacture protocol 
(GeneSpring software, Agilent). Assessment of differential expression was based on 
the highest achieved fold change and the lowest achieved p-value (Welch’s t-test) and 
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1-way-ANOVA with p-value cutoff of 0.05. No assumption of equality of variance 
was made, and Benjamini and Hochberg false discovery rates were used. A cut-off of 
1.5-fold or greater expression difference was set to compare samples. Gene set 
enrichment analysis (GSEA) was performed following the authors guidelines 
(Subramanian et al, 2005). We made use of gene sets representing biological 
pathways or gene ontology categories for biological processes, molecular functions, 
and cellular compartments (http://www. broadinstitute.org/gsea/msigdb/). Each gene 
set was converted from human to mouse using the orthology mapping from The 
Jackson Laboratory (http://bioinf.wehi.edu.au/software/MSigDB). Kaplan-Meier 
survival curves of mice were calculated using SPSS 12.0 software (SPSS, Chicago), 
and differences in survival were assessed by the log rank test. Survival analysis curves 
are representative of at least 21 mice for each genotype. 
 
Cell preparation and FACS analysis 
Salivary glands and primary tumor samples were collected, minced, and incubated for 
90 min at 37°C with digestion buffer containing DMEM/F12 1:1 (Invitrogen), 1.67 
mg/ml collagenase (Invitrogen) and 1.33 mg/ml hyaluronidase (Sigma). The partly 
digested tissues were further treated for 60 minutes at 37°C with dispersion buffer 
containing DMEM/F12 (Invitrogen) and 1.67 mg/ml dispase (Invitrogen). Cell 
suspensions were passed through a stainless filter (70 μm) and centrifuged at 900g for 
5 minutes at 4°C. Pellets were suspended in 10 ml Dulbecco’s modified Eagle/F12 
1:1 medium and washed three times with PBS containing 10% fetal bovine serum 
(Invitrogen). After lysis of red blood cells in ice-cold 0.8% NH4Cl (PBS), cells were 
washed three times with staining buffer (1% FBS/PBS) and incubated for 20 minutes 
with Fc receptor antibody (anti-mouse CD16/CD32; BD Pharmingen). Cells were 
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washed three times with staining buffer and incubated with surface antigen antibodies 
for 45 minutes at 4°C. Primary antibodies were Phycoerythrin (PE)-conjugated rat-
anti CD24 (BD Pharmingen), biotinylated goat-anti CD29 (R&D Systems), 
Allophycocyanin (APC) conjugated CD29 (R&D Systems), mouse-anti CD44 (Cell 
Signaling), and mouse-anti SSEA-1 antibody (R&D Systems). Samples were washed 
and incubated for 30 minutes at 4°C with secondary antibody, streptavidin-APC 
(Invitrogen) or Cy5 (BD Pharmingen). Cells were sorted using FACS Aria (BD 
Biosciences), and surface antigens of cells were analyzed using a FACS caliber (BD 
Biosciences). Data were analyzed using CELLQuest (BD Biosciences). Apoptotic 
cells were excluded by elimination of Dapi-positive cells. Gates were set to exclude 
99.9% of cells labelled with isoform-matched control antibodies conjugated with the 
corresponding fluorochromes. Cytocentrifuge preparations were fixed in 4% 
formaldehyde and stained. 
 
Xenograft and regeneration experiments 
CD24+CD29+-sorted and unsorted cells were transplanted at different dilutions 
subcutaneously into the back skin of NOD/SCID mice. Inhibition by ICG-001 in the 
NOD/SCID mouse xenograft model was investigated (each group n=3) as described 
(Emami et al, 2004).  
 
Cell culture 
Mouse cells were cultured in DMEM/F12 medium supplemented with 20% KSR, 
nonessential minimal amino acids, penicillin/streptomycin, L-glutamine and β-
mercaptoethanol (Invitrogen). Human head and neck carcinoma cell lines 
HNSCCUM-02T and HNSCCUM-03T were cultured as described (Welkoborsky et 
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al, 2003). Cell proliferation was determined using the WST-1 cell proliferation assay 
(Roche) according to the instructions of the manufacturers. To test for non-adherent 
salisphere formation, cells were cultivated in a three-dimensional Matrigel 
(Invitrogen) layer for 24 hours with culture medium and HGF at a concentration of 
100 U/ml. Recombinant HGF was prepared as described (Brinkmann et al, 1995). 
After 24 hours, cells were treated with ICG-001 (Emami et al, 2004), Valproic acid 
(Enzo Life Sciences), 5-azacytidine (Sigma-Aldrich) or CHIR 99021 (Axon 
Medchem). For siRNA treatments, 30 pmol of various small interfering RNA 
(siRNA) (Dharmacon) were transfected by Lipofectamin (Invitrogen) according to the 
manufacture’s protocol. Cells were used for further experiments 48 hours after 
transfection. All siRNA oligonucleotides were purchased from Dharmacon and used 
as pools of four specific oligos (SMARTpool). RNAi oligonucleotide sequences are 
provided in Supplemental Table 6.  
 
Time course experiment 
Salivary gland tumor propagating cells were plated at day 0. Starting from day 1, 25 
μM of ICG-001 was added into culture medium at different time points allowing cells 
at different time points to be collected together and subjected to RT-PCR and Western 
blot analysis. Cells at 0, 6, 12 and 24 h were incubated with equivalent concentration 
of compound vehicle (DMSO, 1:1000) before treated with ICG-001 to exclude the 
impact of vehicle on the cells. 
 
Chromatin-immunoprecipitation (ChIP) 
106 cells were lysed and nuclear extracts prepared. These were incubated with 5 μg of 
antibody (rabbit-anti tri-methyl histone H3 [Lys4; Cell Signaling] and 20 μl Protein A 
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Sepharose beads (Invitrogen) in 500 μl PBS, 5 mg/ml BSA over night at 4°C. The 
beads were re-suspended in 100 μl PBS and 5 mg BSA per ml chromatin, and the 
chromatin was incubated at 4°C on a rotating wheel. The beads were washed 
successively with 1 ml sonication buffer (50 mM Hepes pH 7.9, 140 mM NaCl, 1 mM 
EDTA, 1% Triton X-100, 0.1% Na-deoxycholate, 0.1% SDS, 0.25 mM PMSF and 
protease inhibitor cocktail (Roche), with 1 ml high salt buffer (same as sonication 
buffer except 500 mM NaCl) and with 1 ml LiCl wash buffer (20 mM Tris, pH 8.0, 1 
mM EDTA, 250 mM LiCl, 0.5% NP-40, 0.5% Na-deoxycholate, 0.25 mM PMSF, 
protease inhibitor cocktail. All washing steps were repeated twice and performed on a 
rotating wheel at 4°C. The chromatin was eluted with 50 mM Tris, pH 8.0, 1 mM 
EDTA, 1% SDS, 50 mM NaHCO3 at 65°C for 30 min. Primer sequences used for 
qRT PCR of ChIP samples are provided in Supplemental Table 7. 
 
Ultrastructural analysis of cells by electron microscopy. Cells were fixed with 4% 
formaldehyde, post-fixed with 1% OsO4 for 45 min and contrasted with tannic acid 
and uranyl acetate. Specimens were dehydrated in a graduated ethanol series and 
embedded in PolyBed (Polysciences Europe GmbH). After polymerization, blocks 
were cut at 60–80 nm, contrasted with lead citrate and analyzed in a LEO 906E TEM 
(Zeiss SMT) equipped with a Morada camera (SIS).  
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Figure Legends 
Figure 1. High Wnt/ȕ-catenin and low Bmp signaling characterize head and neck 
squamous cell carcinoma of humans and mice. (A) Serial sections of human salivary 
gland SCC, as analyzed by immunohistochemistry for ȕ-catenin and pSmad1/5/8 or 
by H&E-staining; at tumor fronts, β-catenin is located in nuclei (black arrows) and at 
cell junctions in differentiated, central tumor areas (inset), whereas phospho-
Smad1/5/8 staining is low (inset shows nuclear pSmad1/5/8 staining in tubular cells 
from a differentiated, central area of the same tumor, see arrow). (A*) 
Immunofluorescence for CD24 (in red) and β-catenin (in green, DAPI in blue); CD24 
co-localizes with nuclear β-catenin. st, stroma; tu, tumor. (B) Upper graphs: the 
specific combination of nuclear ȕ-catenin and negative pSmad 1/5/8 was detected in 
75% of aggressive, grade 3 human salivary gland SCC (SG-SCC) and in 63% of 
grade 3 head and neck SCC (HN-SCC). (C) Sections of human HN-SCC, as analyzed 
by immunofluorescence for the stem cell markers CD24 and CD44 (in red) and β-
catenin (in green, DAPI in blue). CD24 and CD44 co-localize with nuclear β-catenin 
in head and neck SCC (quantitation is in B, lower graph, and in C, right panel, in 
yellow letters for grade 2 and grade 3 tumors: the number of double positive cells for 
nuclear β-catenin and CD24 was up-regulated in grade 3 SG-SCC and HN-SCC; 
percentages refer to all tumor cells). The bars give means and standard deviations (*p 
< 0.05, Student’s t-test). P values are as compared with grade 2 tumors. (D) Side view 
of control (wt) and K14Cre;ȕ-catGOF:Bmpr1aLOF double mutant mice at P90 (arrow 
marks a salivary gland tumor). (E) Kaplan Meier survival plot of double mutant 
tumor mice, compared to control and single mutant mice without tumors (each group 
n=21). Bar, 200 μm in A and 50 μm in A*,C. 
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Figure 2. Wnt/ȕ-catenin and Bmp signaling control tumor propagating cells in 
salivary glands of mice. (A) FACS analysis of control (wt) and mutant salivary gland 
cells. High CD24+CD29+ expressing cells are marked by squares (insets), and 
quantification is shown above the squares (details on isotype control staining are 
shown in Supplementary Fig. 3). (B) Sections of control and mutant salivary glands 
stained by immunofluorescence for CD24 (in red, DAPI in blue). (C,D) Identification 
of proliferating cells within the CD24+CD29+ salivary gland cell populations of all 
genotypes by immunofluorescence of cytospins for Ki67 (in red, DAPI in blue). 
Staining of double mutant cells is shown in C, quantification for all genotypes is 
shown in D (n=3). The bars give means and standard deviations (*p < 0.05, Student’s 
t-test). P values are as compared with wildtype cells. Bar, 25 μm.  (E) Quantification 
of proliferation in salivary gland cells of control and mutant mice, as determined by 
immunofluorescence for Ki67 (n=3). The bars give means and standard deviations (*p 
< 0.05, Student’s t-test). P values are as compared with wildtype cells.  (F) Tumor 
outgrowths produced from subcutaneous injections of different cell numbers of 
unsorted or sorted CD24+CD29+ cells from ȕ-catGOF;Bmpr1aLOF double mutant glands 
into the back skin of NOD/SCID mice (each group n=3, details on serial 
transplantations are provided in Supplementary Fig. 4F,G). (G) Tumor formation 
capacity of other sorted subpopulations of cells of ȕ-catGOF;Bmpr1aLOF double mutant 
glands (each group n=3). Single CD24+ or CD29+ or CD24-/CD29- cells did not 
produce tumors. 
 
Figure 3. Salivary gland tumor propagating cells of double mutant mice are 
characterized by stem cell-associated gene expression and specific chromatin marks. 
(A) FAC-sorted CD29+ salivary gland tumor propagating cells were further sorted for 
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CD24 and SSEA-1 expression (high or low expressing cells are gated, insets). (B) 
Immunofluorescence of triple-sorted SSEA-1+ and SSEA-1- cells for nuclear β-
catenin (in red, DAPI in blue). (C) qRT-PCR of highly expressed genes in sorted 
CD24+CD29+ tumor propagating cells at P75-80, which were identified by Affymetrix 
microarray analysis (details shown in Supplementary Fig. 5B,C and Table S4), and 
down-regulation following treatment with the Wnt/β-catenin inhibitor ICG-001 or β-
catenin siRNA (n=4). (D) Analysis of histone trimethylation patterns by 
immunofluorescence for H3K4me3 and H3K27me3 of cytospins of CD24+CD29+ 
salivary gland cells (in red, DAPI in blue, quantification is shown in E). (E) Histone 
trimethylation revealed a profound switch of chromatin marks in the double mutant 
tumor propagating cells. Immunofluorescence for H3K9me3 is shown in 
Supplementary Fig. 5D. (F) H3K4me3 (in red, DAPI in blue) is suppressed in tumor 
propagating cells upon treatment with ICG-001 at 25μM (for quantification of 
H3K9me3 and H3K27me3 after ICG-001 see E). The vertical bars give means and 
standard deviations (*p < 0.05, Student’s t-test). P values are as compared with 
controls (C,F). Bars of magnifications in B, D and F; 25 μm. 
 
Figure 4. Salivary gland tumor propagating cells grow in non-adherent spheres 
(salispheres) and respond to Wnt/β-catenin and HDAC and DNA methylation 
inhibitors. (A) Proliferation of tumor propagating cells and treatment with the Wnt/β-
catenin inhibitor ICG-001, at 25μM in 1% DMSO (n=3). (B) Tumor growth of 
transplanted tumor propagating cells in NOD/SCID mice, and inhibition after intra-
peritoneal administration of ICG-001 at 200 mg/kg (n=5). Red triangles indicate ICG-
001 administration. (C, left panel) Phase contrast images of undifferentiated 
salispheres in Matrigel cultures containing HGF, or differentiated cultures following 
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additional treatment with ICG-001. (C, right panel) Reversion of differentiation of 
sphere cultures in the presence of additional valproic acid (VPA) or 5-azacytidine 
(Aza) (controls are shown in Supplementary Fig. 6H). (D) Phalloidin staining (in 
green; DAPI in blue) of salispheres (left) and differentiated, gland-like structures after 
72 hrs treatment with ICG-001 (right). (E) Quantifications of differentiation of 
spheres from (C) at 72 hrs. In A, B and E, means and standard deviations are shown 
(*p < 0.05, Student’s t-test for A,B; ANOVA for E). P values are as compared with 
control cells or with cells that received combined treatment. Bar in C and D; 100 μm. 
   
Figure 5. Chromatin immunoprecipitation of promoters of chromatin-modifying or 
Wnt/β-catenin target genes. ICG-001-induced downregulation of H3K4me3 precedes 
changes in gene expression in mouse tumor propagating cells and human HN-SCC 
tumor cells. (A,B) H3K4me3 enrichment at the promoters of Mll, Hells, Ash2, Myc, 
and GAPDH or actin genes assessed by chromatin immunoprecipitation (ChIP) of 
mouse ȕ-catGOF;Bmpr1aLOF tumor propagating cells and human head and neck tumor 
cells (HNSCCUM-03T) upon ICG-001 treatment (n=3, I+IV: amplicons from 
promoter-far regions; II+III: amplicons from promoter-near regions). (C) Western 
blot analysis of H3K4me3 in a time course experiment of ICG-001-treated mouse ȕ-
catGOF;Bmpr1aLOF tumor propagating cells. Protein ratios depict H3K4me3 signal 
intensities, normalized to H3, which served as loading control. (D) qRT-PCR analysis 
of samples from the time course experiment depicted in C. Expression changes in the 
differentiation-associated gene Amy1 or Mll, Hells, Ash2 and Myc (genes analyzed by 
ChIP in A) were quantified (n=3). In A,B,D, means and standard deviations are 
shown (*p < 0.05, Student’s t-test). P values are as compared with control cells.  
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Figure 6. Wnt/ȕ-catenin signaling exploits a MLL-dependent H3K4 activity to 
establish and maintain salivary gland tumor propagating cells. Co-expression of 
nuclear ȕ-catenin and nuclear MLL is associated in human salivary gland SCC. (A) 
Western blot analysis of β-catenin in cytoplasmic and nuclear fractions from 
untreated (w/o), CHIR- or ICG-001-treated CD24+CD29+ salivary gland tumor 
propagating cells. (B) Western blot analysis of MLL in nuclear fractions of untreated 
(Ctr), CHIR- or ICG-001-treated tumor propagating cells. α-Tubulin and Lamin in A, 
B are the cytoplasmic or nuclear loading controls, respectively. Protein ratios in A, B 
depict β-catenin or MLL signal intensities, normalized to the corresponding loading 
controls. (C) Analysis of histone trimethylation pattern and proliferation by 
immunofluorescence for H3K4me3 (in red) and Ki67 (in green, DAPI in blue), using 
cytospins of tumor propagating cells upon siRNA-induced knockdown of Mll, β-
catenin, CBP and Ash1, or treatment with the Wnt/β-catenin inhibitor ICG-001 at 
25μM in 1% DMSO (n=3). Quantifications are shown on the right (siCtr, control 
siRNA). (D) Proliferation of tumor propagating cells upon siRNA-induced 
knockdown of Dppa5a, Mll and β-catenin, or treatment with ICG-001 (n=3). (E) 
Quantifications of differentiation of tumor propagating cells in 3D-Matrigel cultures 
upon siRNA-induced knockdown of β-catenin, Mll and Ash1, or treatment with ICG-
001 (n=4). (F) Immunofluorescence analysis for β-catenin (green) and MLL (red, 
DAPI in blue) of human salivary gland SCC (n=13). Two representative tumors are 
shown to distinguish high ȕ-cateninnucl/MLLnucl from low ȕ-cateninnucl/MLLnucl 
tumors. White arrows highlight cells co-expressing nuclear ȕ-catenin and nuclear 
MLL. (G) Nuclear ȕ-catenin correlates with nuclear MLL expression and both 
markers correlate with grade 3 human salivary gland SCC. ȕ-Catenin and MLL 
expression was determined by immunofluorescence analysis in 13 SG-SCC. 
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Associations were determined on an ordinal scale and evaluated using Kendall’s Tau 
coefficient. P-values and patient numbers (n) are indicated. For details see 
Supplementary Fig. 7F,G, Supplementary Table 1 and Materials and Methods. In C-
E, means and standard deviations are shown (*p < 0.05, Student’s t-test). P values are 
as compared with control cells. Bar in C,F; 25 μm.  
 
Figure 7. Model of self-renewal and differentiation of tumor propagating cells in 
salivary gland SCC. (A) Self-renewal depends on active Wnt/β-catenin signals, 
permissive chromatin, and expression of specific target genes, e.g., pluripotency-
associated genes. Potential histone methyltransferases (HMT; MLL) and histone 
acetyltransferases (HAT; CBP) bound to the C-terminus of β-catenin are shown. 
Genetic ablation of β-catenin or siRNAs against Mll inhibits interaction at Wnt-
responsive elements (WRE). ICG-001 blocks association of CBP with β-catenin. (B) 
In contrast, differentiated tumor propagating cells exhibit inactive Wnt/β-catenin 
signaling, repressive chromatin, and down-regulation of pluripotency-associated 
genes. Instead of β-catenin and associates, Groucho and DNMT may be bound to the 
WRE.  
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Supplemental Figure Legends 
Figure S1. Co-expression of Keratin 10 and nuclear -catenin in tumor cells at the invasive 
front of human salivary gland tumors. Anatomy and K14-Cre activity in mouse salivary 
glands. Scheme of breeding and verification of gene recombination. (A) Sections of 
representative human salivary gland tumors (Tu1, Tu2) stained by immunofluorescence for 
cytokeratin 10 (in red) and -catenin (in green, DAPI in blue). White dashed lines indicate 
tumor fronts. White arrow highlight cells co-expressing CK10 and nuclear -catenin; white 
stars highlight CK10negative/nuclear -catenin cells. st; stroma, tu; tumor. (B) Structure of the 
salivary gland (AC; acinar cells, MEC; myoepithelial cells, IDC; intercalated duct cells, DC; 
ductal cells). (C) Keratin14-Cre-mediated expression of LacZ can be detected in ductal but 
not in acinar cells of the mouse salivary gland at P1. (D,E) Verification of K14 expression in 
salivary gland ducts by in situ hybridization. (F) Breeding scheme for the generation of 
compound mutant mice. (G) K14-Cre-mediated recombination of the BmpR1a and -catenin 
genes was evaluated by recombination-specific PCR in wildtype, single mutant and double 
mutant (tumor) cells. Bars in A; 50 μm. Bars in C,D 200 μm. 

Figure S2.Wnt/-catenin and Bmp signaling in the regulation of proliferation, apoptosis, 
and differentiation in mouse salivary glands at P90. Phenotypes in other K14-expressing 
tissues, and cytokeratin 10 expression in transplanted tumors. (A) Histological analysis of 
wildtype, single (K14Cre;Bmpr1aLOF or K14Cre;-catGOF) and tumorigenic double mutant 
(K14Cre;-catGOF:Bmpr1aLOF) salivary glands as revealed by H&E staining and 
immunohistochemistry for cytokeratin 10 (marker for squamous cell carcinoma; insets) (Chu 
and Weiss, 2002). Bars; 250 μm. (B) Serial sections of double mutant mouse SG-SCC, as 
analyzed by immunohistochemistry for -catenin (i) and pSmad1/5/8 (iii) and in situ 
hybridization for the Wnt/-catenin target gene Axin2 (ii). Bars; 100 μm. At tumor fronts, -
catenin is located in nuclei and at cell junctions in central differentiated tumor areas (inset); 
whereas phospho-Smad1/5/8 staining is low (inset shows nuclear pSmad1/5/8 staining in 
tubular cells from a differentiated, central area of the same tumor). (C) Left: quantification of 
apoptosis in salivary glands of wildtype and mutant mice, as determined by 
immunofluorescence for cleaved caspase 3. Middle and right: quantitative real-time PCR for 
the expression of genes important for proliferation (c-myc and CK6), apoptosis (Fas), and 
differentiation (Loricrin). Means and the standard deviations are shown (n=3, *p < 0.05, 
Student’s t-test). P values are as compared with wildtype cells. (D) Sections of skin, 
esophagus and forestomach of wildtype and double mutant mice at P90, as analyzed by H&E 
staining. Bars; 250 μm. 
 
Figure S3. Characterization of expression patterns of CD24, CD29 and CD44 in salivary 
gland cells. (A,B) FACS of wt and mutant salivary gland cells for the expression of CD24 (A) 
and CD29 (B), as indicated by the open histograms and the corresponding isotype controls 
(filled histograms). (C) Overlay of CD24 and CD29 signal intensities of wt and mutant 
salivary gland cells, as analyzed by FACS (single staining are shown in A,B). (D,E) FACS of 
CD44 expression in double mutant CD24+CD29+ tumor propagating cells. Note that 
CD24+CD29+ cells weakly express CD44. CT26 cells (a mouse colon carcinoma cell line) 
served as positive control for high CD44 expression. 
 
Figure S4. Proliferative activity in different subpopulations of double mutant salivary gland 
tumor cells, growth kinetics and cytokeratin expressions in transplanted tumors, and tumor 
propagating cells in secondary and tertiary tumor transplants. (A) Freshly isolated tumor 
cells from double mutant mice were analyzed by FACS for the expression of CD24 and CD29 
(profiles shown in black) and the proliferation marker Ki67 (profile indicated in red). (B) 
Quantification of proliferation in different CD24/CD29 subpopulations of double mutant 
tumor cells (of samples shown in A). Note that proliferation is highest in the high 
CD24+CD29+ expressing tumor propagating cell population (P1) and in CD24lowCD29+ cells 
(P4). (C) Tumor growth kinetics of transplants generated from different numbers of unsorted 
or sorted CD24+CD29+ salivary gland tumor cells after subcutaneous injection in the back 
skin of NOD/SCID mice (n=3). (D) Sections of tumors generated by injection of 
CD24+CD29+ tumor propagating cells of the salivary gland of double mutant mice into back 
skin of NOD/SCID mice. Cytokeratin 10 was highly expressed in differentiated but not in 
dedifferentiated parts of the tumors, as revealed by immunofluorescence analysis (CK10 in 
red, DAPI nuclei staining in blue). (E) Sections of tumors generated by injection of 
CD24+CD29+ tumor propagating cells of the salivary gland of double mutant mice into back 
skin of NOD/SCID mice. CK10 and CK14 are co-expressed by the tumor cells as revealed by 
immunofluorescence analysis (CK10 in red, CK14 in green, DAPI nuclear staining in blue). 
(F) FACS of salivary gland tumor cells from double mutant mice from secondary (2nd) and 
tertiary (3rd) transplanted tumors. High CD24+CD29+ expressing cells are marked by squares 
(insets), and quantification is shown above the squares (details on isotype control staining are 
shown in Supplementary Fig. 3). (G) Tumor outgrowths produced from subcutaneous 
injections of different cell numbers of unsorted or sorted CD24+CD29+ cells from secondary 
and tertiary tumors from double mutant glands into the back skin of NOD/SCID mice (each 
group n=3). Bar in D,E; 100 μm. 
 
Figure S5. Salivary gland CD24+CD29+ tumor propagating cells show increased expression 
of genes associated with maintenance of pluripotency and exhibit an increase in permissive 
and a decrease in repressive chromatin marks. (A) Determination of active Bmp signaling by 
immunofluorescence for phospho-Smad 1/5/8 (in red; DAPI in blue) of cytospins of unsorted 
and CD24+CD29+ double-mutant mouse salivary gland squamous cell carcinoma cells (SG-
SCC). Images from the analysis of two representative SG-SCC are shown. Quantifications are 
shown in (B). Means and the standard deviations are shown and the P value is depicted (n=3, 
Student’s t-test). (C) qRT-PCR of sorted CD24+CD29+ salivary gland cells from single 
mutant and double mutant mice at P80 to validate the salivary gland tumor propagating cell 
gene signature shown in Fig. 3C, which was identified by Affymetrix microarray analysis 
(n=3, *p < 0.05, ANOVA,  P values are as indicated by brackets, details shown in 
Supplementary Fig. 5D and Table S4). (D) Gene signature enriched in salivary gland tumor 
propagating cells of double mutant mice as determined by microarray profiling. Detailed 
expression is shown in Tables S2 and S4. (E) Immunofluorescence analysis for H3K9me3 of 
CD24+CD29+ salivary gland cells (red, DAPI in blue) from wt, single mutant (Bmpr1aLOF or 
-catGOF) and double mutant mice. (F) Western blot analyses of tri-methylated H3K4, H3K27 
and H3K9 from wt, single and double mutant mice (dm1, dm2) and from transplanted tumors 
(T1, T2). Histone 3 (H3) served as loading control. (G) Section of human salivary gland 
squamous cell carcinoma (SG-SCC) stained by immunofluorescence for H3K4me3 (in red) 
and -catenin (in green, DAPI in blue). H3K4me3 co-localizes with nuclear -catenin at the 
tumor fronts (white dotted line). Bars in A,D,F; 50 μm. 
 
Figure S6. The impact of high Wnt/-catenin and low Bmp signaling on the expression of 
stem cell markers and self-renewal in human head and neck cancer. Salispheres of mouse 
tumor propagating cells respond to Wnt/-catenin, HDAC and DNA methylation inhibitors. 
(A) Human head and neck SCC cells (HNSCCUM-03T and HNSCCUM-02T) were analyzed 
by Western blotting for the expression of Axin2, pSmad1/5/8 and CD44. -Tubulin served as 
a loading control. (B) Confirmation of the salivary gland tumor propagating cell-gene 
signature in human head and neck cancer cells, and effects on gene expression following 
treatment with either the Wnt/-catenin activator CHIR or with the inhibitor ICG-001, as 
determined by qRT PCR. (C) Quantification of CD24+CD44+ cell populations in 03T and 02T 
cells treated with ICG-001 or CHIR, as determined by FACS. (D) Quantification of sphere 
formation of 03T and 02T cells treated with ICG-001 or CHIR. (E) H&E staining of a 
differentiated salisphere; inset shows magnified duct-like structures. (F) Differentiated 
salispheres show lumen formation in electron microscopy. The magnification highlights 
secretory granules (asterisk) and tight junctions (arrow). (G) Induction of Amylase 1 (Amy1) 
expression in differentiated salispheres, as detected by qRT PCR (n=3). (H) Phase-contrast 
images of salispheres in Matrigel cultures treated with valproic acid (VPA) and 5-azacytidine 
(Aza). In B,C,D and G, the means and the standard deviations are shown (n=3, *p < 0.05, 
Student’s t-test). P values are as compared with controls. Bars in E,H; 100 μm, in F; 5 μm.  
 
Figure S7. High Wnt/-catenin signals correlate with increased expression of HELLS, 
NR5A2 and MLL in both salivary gland tumor propagating cells of double-mutant mice and 
high grade human head and neck tumors. (A) Western blot analyses of HELLS and NR5A2 
from salivary gland tumor propagating cells from double mutant mice after treatment with 
ICG-001. Tubulin served as loading control. (B) Human head and neck SCC cells (03T and 
02T) were analyzed by immunofluorescence for nuclear -catenin (in green, DAPI in blue) 
and changes in -catenin localization were determined upon treatment with the Wnt/-catenin 
inhibitor ICG-001 at 25μM. (C) Quantification of H3K4me3-positive tumor propagating cells 
upon siRNA-induced knockdown of Mll, -catenin, CBP and Ash1 or treatment with the 
Wnt/-catenin inhibitor ICG-001 at 25μM, as analyzed by immunofluorescence in Figure 6C. 
The means and the standard deviations (SD) are specified (n=3). (D) siRNA efficacy in 
double mutant (-catGOF;Bmpr1aLOF) salivary gland tumor propagating cells. The effect of 
transiently transfected siRNA pools was analyzed by qPCR. Results are normalized for -
actin. (E) Immunofluorescence analysis for CD24 (in green) and MLL (in red, DAPI in blue) 
in salivary glands from wt, single mutant (Bmpr1aLOF or -catGOF) and double mutant mice. 
High power insets and separate channels are shown. (F,G) Associations between nuclear -
catenin, nuclear MLL and the clinical parameter “tumor grade” were measured on an ordinal 
scale and evaluated using Kendall’s Tau (for  and p-values see Figure 6F,G, further details 
are shown in Supplementary Table 1 and Materials and Methods). -catenin and MLL 
expressions were determined by immunofluorescence analysis of human SG-SCC (n=13). (H) 
Quantification of NR5A2 expression in human head and neck cancer revealed increased 
levels in high grade tumors, as determined by immunohistochemistry (n=29, and data not 
shown). The bars give the means and standard deviations (***p <0.001, *p < 0.05, Student’s 
t-test). P values are as compared with siCtr-transfected cells (D) or grade 2 tumors (H). Bars 
in B, E; 25 μm.  
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Table S1: Characteristics of human salivary gland and head and neck SCCs.1 
# Origin SG-SCC
2 
# Sex
Age at diagnosis  
(years) Site Grade 
IHC
-catenin3 
IHC  
pS1/5/83 
IHC 
MLL3 
1 Ch Berlin4 1 M 32 parotid 3 n (n-high) - high 
2 Ch Berlin 2 M 55 parotid 2 n (n-med) - med 
3 Ch Berlin 3 F 64 parotid 3 n (n-med) - med 
4 Ch Berlin 4 F 71 parotid 3 n (n-high) - high 
5 Ch Berlin 5 F 74 parotid 3 n (n-med) - high 
6 Ch Berlin 6 M 76 parotid 3 n (n-med) - high 
7 Ch Berlin 7 F 76 parotid 2 m (n-low) + med 
8 Ch Berlin 8 F 76 parotid 3 n (n-med) - med 
9 Ch Berlin 9 M 76 parotid 3 n (n-high) - high 
10 Ch Berlin 10 F 79 sublingual 3 m (n-low) + med 
11 Ch Berlin 11 M 80 parotid 3 n (n-high) - high 
12 Ch Berlin 12 F 83 parotid 2 m (n-low) + low 
13 Ch Berlin 13 F 94 parotid 2 m (n-low) + low 
14 UH Düss5 14 M 61 parotid 2 n - n.d. 
15 UH Düss 15 F 74 parotid 2 m   + n.d.
16 UH Düss 16 M 76 parotid 2 m + n.d. 
17 UH Düss 17 M 84 parotid 2 m + n.d. 
18 UH Düss 18 F 90 parotid 3 m + n.d. 
    Ø 73.4   ØF 78.1   ØM 67.5      
  HN-SCC6 
#     
   
19 UH Düss 1 M 47 mandible 2 n - n.d. 
20 UH Düss 2 M 49 pharynx 2 m + n.d. 
21 UH Düss 3 F 49 tongue 2 n - n.d. 
22 UH Düss 4 M 51 tongue 3 n - n.d. 
23 UH Düss 5 F 52 larynx 3 m + n.d. 
24 UH Düss 6 M 54 mouth floor 3 n - n.d. 
25 UH Düss 7 M 57 glottis 2 n - n.d. 
26 UH Düss 8 M 58 pharynx 1 m + n.d. 
27 UH Düss 9 M 58 pharynx 2 m + n.d. 
28 UH Düss 10 M 58 tonsil 2 m + n.d. 
29 UH Düss 11 M 59 larynx 2 m + n.d. 
30 UH Düss 12 M 59 larynx 2 n - n.d. 
31 UH Düss 13 M 60 pharynx 2 n - n.d. 
32 UH Düss 14 F 60 pharynx 2 m + n.d. 
33 UH Düss 15 M 61 pharynx 2 n - n.d. 
34 UH Düss 16 M 61 tongue 2 m + n.d. 
35 UH Düss 17 M 65 larynx 1 m - n.d. 
36 UH Düss 18 M 65 mouth floor 2 m + n.d. 
37 UH Düss 19 M 66 larynx 2 m + n.d. 
38 UH Düss 20 M 68 pharynx 2 n - n.d. 
39 UH Düss 21 M 68 mouth floor/tongue 2 n - n.d. 
40 UH Düss 22 M 71 pharynx 2 m + n.d. 
41 UH Düss 23 M 73 tonsil 2 m + n.d. 
42 UH Düss 24 M 73 larynx 2 m + n.d. 
43 UH Düss 25 M 73 tongue 2 m + n.d. 
44 UH Düss 26 M 74 glottis/larynx 2 n - n.d. 
45 UH Düss 27 M 77 pharynx 2 m + n.d. 
46 UH Düss 28 M 78 pharynx 2 m + n.d. 
47 UH Düss 29 M 80 glottis 2 m - n.d. 
    Ø 62.9   ØF 53.7   ØM 64.0      
1Tumor specimens from 47 patients with primary salivary gland and head and neck squamous cell carcinoma (SCC) were 
evaluated. Cases with possible metastatic origin were stringently excluded. Tumour staging and grading was performed 
according to current clinical and pathological classifications (Barnes et al, 2005). 
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2SG-SCC, salivary gland squamous cell carcinoma. Tumors with mucoepidermoid or adenoid origin were stringently excluded 
by our collaborating pathologists. 
3Scoring was based on intensity and percentage of positively stained cells by immunohistochemistry (IHC) for -catenin 
(intracellular localization as analyzed for Fig. 1A: n, nuclear in  20% of the cells; m, membrane; cp, cytoplasmic. Nuclear score 
“n” [in brackets] as analyzed for Fig. 6F,G: low; 5%, medium; 5-25%, high; 25%), p-Smad 1/5/8 (as analyzed for Fig. 1A: -
/detectable in  10% of the cells; +/detectable in  10% of the cells), and MLL (Nuclear score as analyzed for Fig. 6F,G: low; 
5%, medium; 5-20%, high; 20%). n.d.; not determined. 
4Institute of Pathology, Charité University Medicine/UKBF, 12200 Berlin, Germany 
5Department of Otorhinolaryngology, University Hospital Düsseldorf, 40225 Düsseldorf, Germany 
6HN-SCC, head and neck squamous cell carcinoma. 
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Suppl. Table 2: Affymetrix gene profiling of salivary glands at P1.*
[1] = -catGOF
[2] =double mutant
Probe ID Symbol/Description fc [2]/[1] p
1420347_at palate, lung, and nasal epithelium carcinoma associated 66.667 8.22E-06
1447360_at TSC22-related inducible leucine zipper 1b (Tilz1b) 35.211 6.87E-05
1425447_at dickkopf homolog 4 (Xenopus laevis) 16.807 3.02E-06
1441172_at AF4/FMR2 family, member 3 (Aff3), mRNA 12.594 5.09E-04
1437894_at prospero-related homeobox 1 6.024 2.93E-04
1429856_at tetraspanin 18 5.464 3.94E-04
1450781_at high mobility group AT-hook 2 5.291 2.06E-04
1446269_at high mobility group box transcription factor 1 5.291 6.53E-06
1423635_at bone morphogenetic protein 2 4.505 4.22E-05
1422833_at forkhead box A2 4.484 2.23E-04
1422912_at bone morphogenetic protein 4 3.968 3.32E-07
1428816_a_at GATA binding protein 2 3.953 2.18E-04
1416693_at forkhead box C2 3.817 6.93E-05
1441165_s_at calsyntenin 2 3.717 4.91E-05
1420085_at fibroblast growth factor 4 3.717 5.74E-05
1448877_at distal-less homeobox 2 3.676 6.14E-06
1427489_at integrin alpha 8 3.676 4.72E-04
1417278_a_at naked cuticle 1 homolog (Drosophila) 3.676 3.60E-05
1421299_a_at lymphoid enhancer binding factor 1 3.623 1.99E-05
1416101_a_at histone 1, H1c 3.584 5.13E-07
1445123_at Chromobox homolog 1 (Drosophila HP1 beta) (Cbx1), mRNA 3.460 2.56E-05
1419735_at casein kappa 3.425 6.93E-05
1435950_at hairless 3.390 3.00E-04
1439663_at Patched homolog 1 (Ptch1), mRNA 3.390 1.22E-04
1420017_at tetraspanin 8 3.390 6.35E-05
1449559_at homeo box, msh-like 2 3.289 9.60E-05
1418471_at placental growth factor 3.257 1.94E-04
1452240_at bruno-like 4, RNA binding protein (Drosophila) 3.165 8.21E-05
1431166_at chromodomain helicase DNA binding protein 1 3.058 5.07E-05
1416003_at claudin 11 2.950 3.31E-06
1425425_a_at Wnt inhibitory factor 1 2.874 4.74E-05
1422914_at trans-acting transcription factor 5 2.865 2.56E-04
1449470_at distal-less homeobox 1 2.857 3.92E-07
1435790_at olfactomedin 2 2.817 3.11E-04
1449863_a_at distal-less homeobox 5 2.725 1.43E-04
1437060_at olfactomedin 4 2.674 5.24E-04
1453131_at CD300 antigen like family member G 2.591 5.74E-05
1443227_at basic leucine zipper and W2 domains 2 2.584 7.53E-05
1421677_at fibroblast growth factor 20 2.558 1.01E-05
1422655_at patched homolog 2 2.532 5.69E-06
1451629_at limb-bud and heart 2.494 1.07E-06
1437419_at BMP2 inducible kinase 2.469 3.54E-04
1423671_at delta/notch-like EGF-related receptor 2.421 5.97E-05
1441350_at fibroblast growth factor 3 2.410 1.66E-06
1434559_at syntaxin 3 2.398 5.66E-05
1450135_at frizzled homolog 3 (Drosophila) 2.387 3.41E-05
1440274_at CAMP-GEFII 2.370 9.77E-06
1449049_at toll-like receptor 1 2.364 1.60E-04
1459720_x_at Timeless interacting protein (Tipin), mRNA 2.353 2.61E-06
1443087_at CDC23 (cell division cycle 23, yeast, homolog) 2.304 5.15E-06
1450475_at distal-less homeobox 3 2.304 6.01E-04
1422985_at frizzled homolog 1 (Drosophila) 2.273 3.29E-07
1424446_at armadillo repeat containing 7 2.257 1.73E-04
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1435521_at Musashi homolog 2 (Drosophila) 2.252 3.75E-04
1433471_at transcription factor 7, T-cell specific 2.252 1.68E-07
1422537_a_at inhibitor of DNA binding 2 2.227 6.08E-04
1427328_a_at CLIP associating protein 2 2.217 1.42E-04
1456746_a_at Cd99 antigen-like 2 2.203 1.91E-05
1428014_at histone 1, H4h 2.203 1.38E-04
1423259_at inhibitor of DNA binding 4 2.193 6.03E-05
1431053_at M-phase phosphoprotein 9 2.169 1.04E-04
1454086_a_at LIM domain only 2 2.160 1.16E-05
1448886_at GATA binding protein 3 2.151 8.15E-05
1416552_at Dppa5a, developmental pluripotency associated 5A, Esg1, ecat2 2.139 1.99E-04
1428424_at polycomb group ring finger 3 2.137 1.25E-04
1434593_at eukaryotic translation initiation factor 5A2 2.128 1.26E-04
1456341_a_at Kruppel-like factor 9 2.128 4.53E-04
1441339_at chromodomain helicase DNA binding protein 9 2.123 2.81E-06
1421341_at axin2 2.114 1.81E-05
1425611_a_at cut-like 1 (Drosophila) 2.105 1.48E-04
1429217_at zinc finger protein 655 2.075 4.04E-04
1450082_s_at ets variant gene 5 2.066 1.33E-05
1436218_at leucine-rich repeat-containing G protein-coupled receptor 6 2.066 4.98E-06
1445315_at WNK lysine deficient protein kinase 2 2.066 6.16E-04
1430216_at zinc finger protein 292 2.058 9.40E-05
1449317_at CASP8 and FADD-like apoptosis regulator 2.053 4.70E-05
1427540_at ZW10 interactor 2.045 9.09E-06
1448925_at twist homolog 2 (Drosophila) 2.033 3.61E-04
1419380_at zinc finger protein 423 2.024 3.69E-06
1441938_x_at Cdk5 and Abl enzyme substrate 1 2.020 4.31E-05
1455280_at Fras1 related extracellular matrix protein 1 2.016 2.64E-05
1440086_at ring finger protein 182 2.000 4.71E-04
1437904_at developmentally regulated RNA binding protein 1 1.965 4.06E-04
1446259_at CD180 antigen (Cd180), mRNA 1.961 3.54E-05
1437395_at zinc finger, CCHC domain containing 11 1.961 1.08E-04
1427526_at FGFR1 oncogene partner 2 1.949 1.02E-04
1455823_at Bardet-Biedl syndrome 4 homolog (human) 1.942 2.27E-04
1438815_at histone 2, H2aa2 1.927 5.80E-04
1419848_x_at toll-like receptor 7 1.927 3.30E-06
1460725_at xeroderma pigmentosum, complementation group A 1.927 5.50E-05
1448158_at syndecan 1 1.923 5.95E-06
1416129_at ERBB receptor feedback inhibitor 1 1.919 1.82E-05
1448742_at snail homolog 1 (Drosophila) 1.916 6.53E-05
1443962_at transcription factor Dp 2 1.916 2.60E-04
1452021_a_at hairy and enhancer of split 6 (Drosophila) 1.908 4.75E-06
1425895_a_at inhibitor of DNA binding 1 1.905 5.82E-04
1457276_at SNF1-like kinase 2 1.894 4.21E-06
1453688_at CWF19-like 2, cell cycle control (S. pombe) 1.890 1.17E-04
1457586_at RAS p21 protein activator 2 (Rasa2), mRNA 1.873 5.35E-05
1436469_at Bromodomain containing 7 (Brd7), mRNA 1.862 4.86E-04
1434196_at DnaJ (Hsp40) homolog, subfamily A, member 4 1.862 4.81E-05
1455717_s_at dishevelled associated activator of morphogenesis 2 1.859 1.78E-04
1416451_s_at taube nuss 1.859 1.94E-05
1437162_at GPI-anchored membrane protein 1 (Gpiap1), mRNA 1.855 2.13E-05
1445314_at ets variant gene 1 1.852 2.01E-04
1459910_at tankyrase, TRF1-interacting ankyrin-related ADP-ribose polymerase 1.845 3.65E-05
1416630_at inhibitor of DNA binding 3 1.825 2.65E-05
1424614_at FGF receptor activating protein 1 1.818 4.43E-05
1429634_at zinc finger protein 580 1.815 1.05E-04
1443002_at zinc finger RNA binding protein 1.805 2.92E-04
1429962_at CCAAT/enhancer binding protein zeta 1.799 5.56E-05
1457327_at SNF2 histone linker PHD RING helicase 1.786 7.95E-07
1457038_at Fras1 related extracellular matrix protein 2 1.783 2.94E-05
1443471_at zinc finger and BTB domain containing 20 1.783 2.02E-04
1425107_a_at leukemia inhibitory factor receptor 1.779 2.04E-05
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1451281_at zinc finger protein 96 1.779 2.41E-05
1422031_a_at zinc finger, A20 domain containing 3 1.779 2.10E-04
1422470_at BCL2/adenovirus E1B 19kDa-interacting protein 1, NIP3 1.776 2.68E-06
1419816_s_at ERBB receptor feedback inhibitor 1 1.776 1.02E-04
1428574_a_at chimerin (chimaerin) 2 1.770 3.75E-04
1424074_at basic transcription factor 3-like 4 1.767 7.20E-08
1419716_a_at POU domain, class 2, transcription factor 1 1.764 2.12E-04
1456351_at bromodomain containing 8 1.761 2.27E-04
1448662_at frizzled homolog 6 (Drosophila) 1.754 3.08E-04
1425464_at GATA binding protein 6 1.751 2.84E-04
1418176_at vitamin D receptor 1.748 8.72E-07
1429399_at ring finger protein 125 1.745 4.02E-05
1441467_at Tetraspanin 5 (Tspan5), mRNA 1.730 9.28E-05
1417958_at tetraspan 1 1.727 2.04E-07
1455188_at Eph receptor B1 1.724 3.03E-05
1443240_at Glypican 3, mRNA (cDNA clone MGC:35964 IMAGE:4973409) 1.724 3.22E-04
1423040_at basic leucine zipper and W2 domains 1 1.721 1.81E-04
1428253_at chromatin modifying protein 2B 1.715 2.73E-05
1419144_at CD163 antigen 1.712 1.82E-06
1440341_at Colony stimulating factor 1 receptor (Csf1r), mRNA 1.712 3.25E-04
1434033_at transducin-like enhancer of split 1, homolog of Drosophila E(spl) 1.712 2.02E-05
1427300_at LIM homeobox protein 8 1.706 9.39E-06
1427200_at zinc finger, RAN-binding domain containing 1 1.698 3.45E-06
1449314_at zinc finger protein, multitype 2 1.678 1.32E-05
1444667_at bromodomain, testis-specific 1.675 9.94E-05
1448789_at aldehyde dehydrogenase family 1, subfamily A3 1.667 2.33E-05
1417182_at DnaJ (Hsp40) homolog, subfamily A, member 2 1.664 3.22E-04
1438239_at midline 1 1.661 1.63E-05
1448147_at tumor necrosis factor receptor superfamily, member 19 1.661 6.21E-05
1428396_at SMAD specific E3 ubiquitin protein ligase 1 1.658 1.14E-04
1447944_at zinc finger with KRAB and SCAN domains 1 1.658 2.19E-04
1419368_a_at ring finger protein 138 1.656 1.03E-04
1457441_at early B-cell factor 1 1.647 3.28E-06
1426152_a_at kit ligand 1.647 7.29E-07
1451191_at cellular retinoic acid binding protein II 1.639 1.13E-04
1418147_at transcription factor AP-2, gamma 1.639 7.92E-08
1426151_a_at syntaxin 3 1.634 5.37E-05
1448042_s_at Rnf2, ring finger protein 2 AI326319, AI450156, AU019207, Ring1B 1.626 2.80E-05
1441042_at fibroblast growth factor 1 1.626 2.01E-04
1421412_at goosecoid 1.626 6.17E-06
1420615_at ash2 (absent, small, or homeotic)-like (Drosophila) 1.626 1.07E-05
1458450_at zinc finger RNA binding protein 1.623 1.21E-05
1423702_at H1 histone family, member 0 1.621 5.80E-06
1422932_a_at vav 1 oncogene 1.621 5.27E-07
1418671_at calpain 5 1.616 4.40E-04
1422021_at sprouty homolog 4 (Drosophila) 1.613 5.05E-05
1448366_at syntaxin 1A (brain) 1.613 6.67E-06
1440585_at syntaxin 6 1.613 1.76E-04
1460441_at zinc finger, X-linked, duplicated A 1.613 6.27E-06
1434949_at armadillo repeat containing 8 1.608 6.70E-05
1427956_at polycomb group ring finger 1 1.608 1.37E-04
1416111_at CD83 antigen 1.603 6.06E-07
1427941_at Dicer1, Dcr-1 homolog (Drosophila) 1.603 1.48E-06
1427454_at homeo box C6 1.603 7.72E-05
1451739_at Kruppel-like factor 5 1.603 5.55E-08
1417839_at claudin 5 1.600 3.16E-04
1425555_at CDC2-related kinase 7 1.597 8.02E-06
1441544_at Cyclin M3 (Cnnm3), mRNA 1.597 2.81E-07
1421298_a_at homeodomain interacting protein kinase 1 1.597 1.29E-04
1446349_at zinc finger protein 78 1.597 4.09E-06
1421943_at transforming growth factor alpha 1.595 2.78E-06
1446048_at Cadherin 11 (Cdh11), mRNA 1.592 5.51E-05
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1427618_at cadherin 9 1.592 2.44E-06
1435903_at CD300A antigen 1.592 1.17E-05
1416895_at ephrin A1 1.592 7.44E-06
1454880_s_at Bcl2 modifying factor 1.590 1.52E-04
1451156_s_at very low density lipoprotein receptor 1.590 2.75E-04
1423528_at breast carcinoma amplified sequence 3 1.585 4.32E-05
1429086_at grainyhead-like 2 (Drosophila) 1.585 6.98E-05
1419126_at homeo box D9 1.585 2.65E-04
1418213_at keratin complex 1, acidic, gene 23 1.585 2.44E-07
1419356_at Kruppel-like factor 7 (ubiquitous) 1.582 1.14E-04
1420376_a_at H3 histone, family 3B 1.580 2.89E-05
1438495_at topoisomerase (DNA) I 1.580 1.27E-04
1425693_at Braf transforming gene 1.577 4.40E-06
1442757_at leucine-rich repeats and calponin homology (CH) domain containing 1 1.577 1.37E-06
1449732_at zinc finger proliferation 1 1.575 9.62E-05
1434234_at zinc finger protein 341 1.575 3.62E-06
1444328_at clathrin, light polypeptide (Lca) 1.572 6.46E-06
1424355_a_at transcriptional regulator, SIN3B (yeast) 1.570 2.90E-06
1421151_a_at Eph receptor A2 1.567 2.96E-04
1439638_at Erbb2 interacting protein 1.567 2.09E-06
1419874_x_at zinc finger and BTB domain containing 16 1.567 9.97E-05
1426753_at PHD finger protein 17 1.565 1.66E-06
1453247_at zinc fingerprotein 618 1.565 9.53E-06
1416511_a_at CDC42 effector protein (Rho GTPase binding) 4 1.563 2.55E-04
1418285_at ephrin B1 1.563 2.82E-05
1417394_at Kruppel-like factor 4 (gut) 1.563 1.25E-05
1455658_at CGG triplet repeat binding protein 1 1.560 3.24E-05
1452718_at E3 ubiquitin protein ligase, HECT domain containing, 1 1.560 8.96E-05
1426332_a_at claudin 3 1.558 6.84E-04
1439079_a_at Erbb2 interacting protein 1.558 3.88E-06
1448765_at Fyn proto-oncogene 1.555 1.46E-05
1418478_at LIM domain only 1 1.555 2.93E-06
1426981_at proprotein convertase subtilisin/kexin type 6 1.550 4.61E-06
1428034_a_at tumor necrosis factor receptor superfamily, member 9 1.548 7.45E-06
1424298_at zinc finger protein 282 1.548 4.77E-06
1419474_a_at ets homologous factor 1.546 2.94E-07
1424638_at cyclin-dependent kinase inhibitor 1A (P21) 1.543 4.10E-04
1434370_s_at Fas-associated factor 1 1.543 4.14E-07
1418581_a_at LIM motif-containing protein kinase 2 1.543 9.36E-05
1437657_at zinc finger protein 291 1.543 7.10E-06
1454305_at chromobox homolog 3 (Drosophila HP1 gamma) 1.541 7.20E-04
1455368_at zinc finger, DHHC domain containing 3 1.541 4.87E-05
1423805_at disabled homolog 2 (Drosophila) 1.538 5.69E-07
1453848_s_at zinc finger, BED domain containing 3 1.538 6.44E-06
1421005_at centrosomal protein 1 1.536 1.13E-05
1457577_at Ephrin B2 (Efnb2), mRNA 1.536 7.94E-05
1424127_at eyes absent 2 homolog (Drosophila) 1.536 2.93E-06
1441635_at Germ cell nuclear factor protein (Nr6a1) 1.536 2.42E-05
1455725_a_at H3 histone, family 3B 1.536 5.76E-05
1419654_at transducin-like enhancer of split 3, homolog of Drosophila E(spl) 1.536 3.29E-05
1428634_at TWIST neighbor 1.536 1.89E-04
1456639_at zinc finger protein 398 1.536 1.56E-05
1451696_at zinc finger protein 64 1.536 2.78E-08
1449126_at zinc finger protein 90 1.536 1.66E-06
1425092_at cadherin 10 1.534 3.09E-05
1439019_at Fraser syndrome 1 homolog (human) 1.531 1.02E-05
1431993_a_at ring finger protein 38 1.531 1.60E-04
1444246_at chromodomain helicase DNA binding protein 2 1.527 9.26E-07
1433507_a_at high mobility group nucleosomal binding domain 2 1.527 2.05E-07
1450267_at toll-like receptor 8 1.527 2.62E-05
1428378_at zinc finger CCCH type, antiviral 1 1.527 7.87E-06
1452504_s_at chitobiase, di-N-acetyl- 1.524 2.97E-05
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1426124_a_at CDC-like kinase 1 1.522 4.48E-04
1423203_a_at centrin 1 1.520 3.93E-05
1453415_at zinc finger CCCH type containing 6 1.520 3.85E-05
1419307_at tumor necrosis factor receptor superfamily, member 13c 1.517 1.26E-05
1435071_at zinc finger, FYVE domain containing 1 1.517 5.08E-05
1439080_at Erbb2 interacting protein 1.515 2.55E-04
1435608_at zinc and ring finger 3 1.515 7.58E-06
1434236_at zinc finger, DHHC domain containing 20 1.515 3.33E-06
1437201_at leucine rich repeat containing 4C 1.513 1.23E-06
1419369_at ring finger protein 138 1.513 6.77E-05
1456912_at zinc finger protein 691 1.513 2.30E-05
1420745_a_at cyclin D-type binding-protein 1 1.511 3.78E-04
1445635_at Eph receptor A7, mRNA (cDNA clone MGC:14056 IMAGE:3991628) 1.508 4.73E-07
1449295_at transcriptional regulator protein 1.508 2.84E-05
1434651_a_at claudin 3 1.506 6.78E-05
1421604_a_at Kruppel-like factor 3 (basic) 1.506 1.12E-05
1425635_at tyrosine kinase, non-receptor, 1 1.506 3.03E-04
1420675_at zinc finger protein 113 0.664 3.65E-04
1429111_at talin 2 0.663 1.39E-06
1448837_at villin 1 0.663 8.08E-06
1416757_at Zwilch, kinetochore associated, homolog (Drosophila) 0.663 1.95E-04
1459009_at Utrophin 0.662 3.35E-07
1424789_at GLI-Kruppel family member HKR2 0.661 3.29E-04
1434824_at bromodomain adjacent to zinc finger domain, 1B 0.661 4.18E-04
1459589_at crystallin, lamda 1 0.658 4.71E-04
1419979_s_at cAMP responsive element binding protein 3 0.657 4.54E-04
1433592_at calmodulin 1 0.657 1.00E-06
1419573_a_at lectin, galactose binding, soluble 1 0.656 4.00E-05
1445534_at Filamin, beta, mRNA (cDNA clone IMAGE:3488025) 0.655 8.48E-05
1438861_at basonuclin 2 0.654 1.49E-07
1420631_a_at bladder cancer associated protein homolog (human) 0.654 3.66E-05
1449233_at basic helix-loop-helix domain containing, class B, 8 0.652 3.29E-04
1438498_at zinc finger, MYND domain containing 15 0.652 3.31E-04
1423505_at transgelin 0.651 2.61E-05
1451537_at chitinase 3-like 1 0.651 3.94E-06
1452968_at collagen triple helix repeat containing 1 0.650 1.38E-04
1448594_at WNT1 inducible signaling pathway protein 1 0.648 8.58E-06
1417067_s_at chaperone, ABC1 activity of bc1 complex like (S. pombe) 0.648 7.80E-06
1422748_at zinc finger homeobox 1b 0.647 2.61E-06
1441198_at zinc finger protein 39 0.647 2.92E-05
1458141_at CAMP specific phosphodiesterase 7B (PDE7B gene) 0.646 7.38E-05
1416246_a_at coronin, actin binding protein 1A 0.646 4.05E-06
1421251_at zinc finger protein 40 0.646 2.28E-04
1456405_at death inducer-obliterator 1 0.645 3.87E-05
1450416_at chromobox homolog 5 (Drosophila HP1a) 0.641 1.26E-04
1452265_at CLIP associating protein 1 0.641 8.21E-06
1417457_at CDC28 protein kinase regulatory subunit 2 0.641 8.39E-05
1422308_a_at lectin, galactose binding, soluble 7 0.641 1.36E-04
1438817_at DNA2 DNA replication helicase 2-like (yeast) 0.640 3.07E-06
1426808_at lectin, galactose binding, soluble 3 0.640 3.30E-05
1424698_s_at grancalcin 0.639 4.38E-04
1438833_at cancer susceptibility candidate 5 0.638 7.64E-07
1437643_at centromere protein J 0.638 1.63E-04
1428460_at synapsin II 0.637 3.34E-05
1416265_at calpain 10 0.637 1.61E-04
1448289_at collapsin response mediator protein 1 0.637 6.31E-05
1420863_at dynactin 4 0.637 4.92E-05
1423691_x_at keratin complex 2, basic, gene 8 0.637 1.20E-05
1427884_at procollagen, type III, alpha 1 0.635 6.14E-06
1435781_at cullin associated and neddylation disassociated 1 0.632 1.20E-06
1456483_at zinc finger protein 9 0.629 4.69E-04
1424629_at breast cancer 1 0.627 1.67E-05
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1430139_at helicase, lymphoid specific 0.627 5.52E-06
1439436_x_at inner centromere protein 0.626 2.64E-05
1439945_at zinc finger protein 449 0.626 2.08E-05
1418133_at B-cell leukemia/lymphoma 3 0.626 4.41E-05
1441375_at Leucine-rich repeats and immunoglobulin-like domains 1 (Lrig1), mRNA 0.623 7.33E-05
1422279_at Friend virus susceptibility 1 0.622 2.81E-06
1418495_at zinc finger CCCH type containing 8 0.620 3.50E-06
1433623_at zinc finger protein 367 0.620 1.09E-04
1422481_at keratin complex 2, basic, gene 1 0.620 1.36E-07
1454849_x_at clusterin 0.618 4.51E-05
1427290_at keratin complex 2, basic, gene 19 0.614 5.50E-05
1434201_at Chordin-like 1 (Chrdl1), mRNA 0.612 1.76E-07
1450536_s_at keratin associated protein 12-1 0.612 4.51E-06
1425356_at zinc finger protein 142 0.612 2.80E-05
1439407_x_at transgelin 2 0.611 8.05E-07
1437788_at trans-acting transcription factor 6 0.609 2.49E-04
1439631_at zinc finger, CCHC domain containing 11 0.608 1.70E-05
1450842_a_at centromere autoantigen A 0.604 9.42E-05
1439030_at GDP-mannose pyrophosphorylase B 0.604 1.01E-05
1428503_a_at NFKB inhibitor interacting Ras-like protein 1 0.598 1.20E-04
1416083_at zinc finger, A20 domain containing 2 0.597 1.56E-05
1418735_at keratin complex 2, basic, gene 4 0.597 6.76E-05
1436095_at chromodomain helicase DNA binding protein 5 0.596 7.68E-05
1428650_at tensin 1 0.596 1.99E-04
1448467_a_at tangerin 0.595 8.37E-07
1421460_at desmocollin 1 0.593 1.00E-04
1427366_at keratin associated protein 3-1 0.593 1.01E-05
1437355_at zinc finger, CCHC domain containing 5 0.592 1.31E-04
1451484_a_at synapsin I 0.585 4.82E-06
1437685_x_at fibromodulin 0.580 1.25E-06
1451637_a_at mucin 10, submandibular gland salivary mucin 0.579 1.02E-04
1451997_at zinc finger protein 426 0.578 3.35E-06
1455187_at zinc finger and BTB domain containing 40 0.576 8.66E-06
1444043_at GLI-Kruppel family member GLI3 (Gli3), mRNA 0.569 6.45E-06
1418608_at calmodulin-like 3 0.567 8.83E-05
1455113_at armadillo repeat containing 8 0.562 9.25E-07
1427348_at zinc finger CCCH type containing 12A 0.562 1.07E-04
1417878_at E2F transcription factor 1 0.561 2.93E-05
1429347_at Bcl2-like 14 (apoptosis facilitator) 0.558 2.01E-05
1426471_at zinc finger protein 52 0.557 1.19E-04
1424407_s_at chromobox homolog 6 0.555 2.19E-05
1417917_at calponin 1 0.554 9.53E-06
1425705_a_at ERO1-like beta (S. cerevisiae) 0.554 1.60E-05
1418091_at transcription factor CP2-like 1 0.553 5.57E-05
1415948_at cellular repressor of E1A-stimulated genes 1 0.549 1.78E-04
1439040_at centromere protein E 0.549 3.95E-06
1430669_at keratin associated protein 4-7 0.547 5.97E-05
1457571_at zinc finger protein 68 0.546 3.41E-07
1447812_x_at filamin C, gamma (actin binding protein 280) 0.544 1.82E-05
1423809_at transcription factor 19 0.542 2.08E-05
1417552_at fibroblast activation protein 0.540 1.44E-04
1422747_at CHK2 checkpoint homolog (S. pombe) 0.536 5.71E-07
1448788_at Cd200 antigen 0.532 4.32E-04
1433862_at extra spindle poles-like 1 (S. cerevisiae) 0.532 6.56E-08
1427179_at keratin complex 1, acidic, gene 3 0.528 4.73E-06
1451611_at HRAS like suppressor 3 0.526 9.14E-07
1422582_at leptin 0.525 3.82E-04
1452166_a_at keratin complex 1, acidic, gene 10 0.519 1.51E-04
1455642_a_at tetraspanin 17 0.519 3.56E-06
1424218_a_at cAMP responsive element binding protein 3-like 4 0.518 9.73E-06
1419295_at cAMP responsive element binding protein 3-like 1 0.517 6.05E-06
1418063_at keratocan 0.515 7.97E-05
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1436186_at E2F transcription factor 8 0.515 2.98E-06
1433681_x_at calpain 3 0.515 2.94E-05
1460082_at inhibitor of growth family, member 3 0.512 9.59E-05
1448835_at E2F transcription factor 6 0.505 1.37E-05
1457275_at desmuslin 0.501 3.13E-04
1442140_at tenascin N 0.500 1.10E-05
1418440_at procollagen, type VIII, alpha 1 0.499 4.76E-07
1422954_at zinc finger protein 60 0.497 5.33E-06
1440770_at B-cell leukemia/lymphoma 2 0.494 2.40E-05
1434573_at TRAF3 interacting protein 3 0.494 1.51E-05
1442542_at eyes absent 4 homolog (Drosophila) 0.493 2.16E-04
1446636_at tensin 3 0.492 2.19E-05
1418804_at succinate receptor 1 0.491 1.27E-06
1424567_at tetraspan 2 0.490 2.87E-05
1427161_at centromere autoantigen F 0.480 2.36E-05
1443931_at Zinc finger protein 617 (Zfp617), mRNA 0.478 8.22E-07
1418093_a_at epidermal growth factor 0.473 1.73E-04
1425262_at CCAAT/enhancer binding protein (C/EBP), gamma 0.469 2.45E-04
1417268_at CD14 antigen 0.469 5.95E-04
1419521_at zinc finger protein 94 0.464 4.15E-04
1431035_at dishevelled associated activator of morphogenesis 1 0.464 1.75E-05
1417644_at sarcospan 0.464 6.85E-05
1457424_at eyes absent 1 homolog (Drosophila) 0.462 3.80E-05
1426180_a_at submaxillary gland androgen regulated protein 2 0.462 5.01E-08
1445256_at Vinculin, mRNA (cDNA clone MGC:6134 IMAGE:3495710) 0.460 6.82E-06
1421355_at transglutaminase 3, E polypeptide 0.456 5.05E-05
1429067_at calpain, small subunit 2 0.444 3.33E-04
1428052_a_at zinc finger, MYM domain containing 1 0.444 4.19E-05
1437095_at tetraspanin 18 0.442 3.24E-06
1454884_at BTB (POZ) domain containing 4 0.439 4.01E-04
1435005_at centromere protein E 0.433 5.74E-06
1425237_at keratin associated protein 16-8 0.421 2.05E-05
1420358_at keratin associated protein 13 0.418 2.25E-08
1445032_at Death associated protein kinase 1 (Dapk1), mRNA 0.418 3.63E-05
1416025_at fibrinogen, gamma polypeptide 0.416 9.41E-06
1431727_at submandibular gland protein C 0.411 1.39E-05
1417686_at lectin, galactose binding, soluble 12 0.407 3.79E-04
1422814_at asp (abnormal spindle)-like, microcephaly associated (Drosophila) 0.404 2.19E-05
1456228_x_at myelin basic protein 0.404 7.48E-05
1416658_at frizzled-related protein 0.401 1.78E-04
1460218_at CD52 antigen 0.397 3.00E-05
1416342_at tenascin C 0.391 1.18E-04
1449919_at keratin associated protein 6-2 0.382 6.36E-06
1455519_at desmoglein 1 beta 0.375 1.56E-06
1423010_at sacsin 0.358 2.16E-04
1421691_at keratin associated protein 16-7 0.357 9.29E-07
1420466_at salivary protein 2 0.351 1.37E-05
1424528_at cell growth regulator with EF hand domain 1 0.347 1.28E-05
1421855_at fibrinogen-like protein 2 0.342 7.62E-05
1450633_at calmodulin 4 0.342 9.47E-06
1429540_at cornifelin 0.339 2.71E-06
1430731_at keratin associated protein 2-4 0.336 5.41E-07
1424531_a_at transcription elongation factor A (SII), 3 0.331 3.45E-06
1449073_at filamin C, gamma (actin binding protein 280) 0.317 1.27E-06
1422640_at protocadherin beta 9 0.315 6.16E-04
1459897_a_at suprabasin 0.313 2.81E-06
1424529_s_at cell growth regulator with EF hand domain 1 0.309 1.40E-06
1422837_at sciellin 0.308 1.19E-04
1455900_x_at transglutaminase 2, C polypeptide 0.302 3.11E-06
1443745_s_at dentin matrix protein 1 0.291 8.52E-06
1416455_a_at crystallin, alpha B 0.287 1.11E-05
1421589_at keratin complex 1, acidic, gene 1 0.286 7.06E-08
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1420183_at Loricrin (Lor), mRNA 0.273 4.86E-07
1431255_at calreticulin 3 0.244 5.08E-05
1426043_a_at calpain 3 0.218 3.23E-07
1418314_a_at ataxin 2 binding protein 1 0.212 2.01E-04
1417979_at tenomodulin 0.207 1.70E-04
1435649_at nexilin 0.203 2.10E-08
1423253_at myelin protein zero 0.201 1.11E-04
1422588_at keratin complex 2, basic, gene 6b 0.198 5.57E-05
1458000_at desmoglein 1 alpha 0.197 6.25E-06
1422654_at sarcoglycan, alpha (dystrophin-associated glycoprotein) 0.186 2.34E-05
1445824_at zinc finger protein 458 0.186 8.34E-06
1416776_at crystallin, mu 0.180 3.79E-05
1420751_at keratin associated protein 6-1 0.180 2.99E-07
1422529_s_at calsequestrin 2 0.167 1.99E-05
1448168_a_at salivary protein 1 0.164 9.03E-05
1427735_a_at actin, alpha 1, skeletal muscle 0.162 2.09E-07
1418413_at caveolin 3 0.157 1.55E-06
1459266_at ARP3 actin-related protein 3 homolog (yeast) (Actr3), mRNA 0.130 1.94E-04
1418951_at taxilin beta 0.129 9.86E-07
1427211_at keratin associated protein 8-1 0.128 1.06E-04
1436867_at sarcalumenin 0.122 7.54E-06
1448745_s_at loricrin 0.110 1.13E-04
1423238_at integrin beta 1 binding protein 2 0.109 8.05E-06
1448932_at keratin complex 1, acidic, gene 16 0.109 4.43E-06
1435191_at corneodesmosin 0.108 5.84E-04
1460185_at keratin complex 2, basic, gene 18 0.104 2.37E-06
1418742_at keratin complex 1, acidic, gene 4 0.104 9.74E-05
1428007_at keratin associated protein 13-1 0.099 2.53E-06
1422598_at calsequestrin 1 0.098 2.19E-04
1420409_at keratin complex 1, acidic, gene 24 0.093 2.35E-08
1420884_at sarcolipin 0.077 3.79E-06
1448327_at actinin alpha 2 0.070 3.40E-05
1425382_a_at aquaporin 4 0.068 2.93E-04
1418677_at actinin alpha 3 0.067 1.57E-04
1427751_a_at keratin complex 1, acidic, gene 5 0.054 4.32E-05
1447456_x_at demilune cell and parotid protein ; cDNA sequence BC005655 0.050 9.98E-06
1435585_at transcription elongation factor A (SII)-like 7 0.049 4.59E-06
1451551_at keratin complex 2, basic, gene 16 0.049 4.73E-05
1452957_at keratin associated protein 3-3 0.041 9.06E-06
*List of differentially expressed genes that distinguish between salivary gland tissue from double mutant mice and
single mutant -catGOF mice according to gene chip analysis. Affymetrix probe set ID (Probe ID), gene description,
fold change (fc), and p-value (p) are shown. Grey-marked genes were specifically discussed in the text.
et al.
	




	

 !
vs.!
	!
"
  #  $ %&' 
 (
			

	

     				
 
!"#		$

	%&
    ' (  ' 			
)"#
 		$*	%++&
 
"#,-./'0,  (   0		 !	#"
	

# 	
 	')	*
"


-	-+*			 -..-+*	 ( (   -	*+*			
$	) 	%+
1"2
 	&
 12-..-3-.  ( 4 4 -*					
 5"5	
 *	*+*	
 /-..-3-.-/6  ' 4 ( 		
 5"5	 "
"	

 "")*	*+*	
""
 


-/6,/,/2   ( '4 		
 5"5	 ""
 

7 ))		  " 0-0.6/.-0.-2823 ' ( 4  * 	 +")
*"#	9"

	#%+: ! "
"
 	*	
	
 tumor-propagating  CD24+CD29+ 

vs)!
	CD24+CD29+

"*+
  #  $ %&' 
 (
60.2-..0./2678./,6 4 '   +" 
#	5	"#	


%	  *	
 		 
	
 
"+ 	 *!	   "%	# 
 5+ 
  ,  "%	# #"" *	

*"#	 " 
 	 # %	*	  
  ,; 
 		# 	 %+ 		 
	 	 *!#	 +
 
 $&
		 
	
 :		 			  % 
!	   !	 6"	*  	 7%
	 $6
 71< 1" 2
 	;
!=>>:::%"# 	>
	>#
 %&  ?	   *	
 #%	 ") 		
  *	   	*! 		 
	  *!#	 
*"	 $& 
"# ?	 	 *!#	 
*"	 $&  @7 :		 **	 %+  	 5	 ; 	 5	 ;  @7A   *	

  ) *	 *!#	")
	* ) *		
	 "%	#
 5+
*"#	"
 	#%	*	 

Wend et al., Suppl. Table ', page 1/3
Suppl Table ,: Affymetrix gene profiling of CD24+CD29+ salivary gland cells at P80*
Salivary gland CD24+CD29+ ((!!cellgene signature
[1] = Bmpr1aLOF
[2] = -catGOF
[3] =double mutant
Probe ID Symbol UniGene fc [3] / [1] Regulation [3] / [1] p [3] / [1] fc [3] / [2] Regulation [3] / [2] p [3] / [2]
1425642_at Cep290 Mm.229114 3.891 up 8.30E-05 5.098 up 6.83E-04
1420411_a_at Pi4k2b Mm.248647 3.571 up 3.82E-04 2.638 up 1.60E-05
1420330_at Clec4e Mm.248327 3.369 up 3.82E-06 1.580 up 1.32E-05
1437689_x_at Clu Mm.200608 2.663 up 3.27E-04 2.354 up 1.36E-05
1451798_at Il1rn Mm.882 2.310 up 3.76E-04 1.584 up 1.73E-06
1447084_at Nfatc1 Mm.329560 2.216 up 8.39E-04 1.026 up 1.42E-06
1449254_at Spp1 Mm.288474 2.184 up 2.37E-04 1.306 up 5.46E-05
1421473_at Il1a Mm.15534 2.155 up 1.10E-04 1.549 up 2.78E-07
1447669_s_at Gng4 Mm.215394 2.066 up 9.23E-05 1.533 up 1.68E-04
1449984_at Cxcl2 Mm.4979 2.050 up 3.79E-04 1.130 up 1.34E-04
1442376_at Ablim1 Mm.217161 1.967 up 2.93E-06 2.951 up 3.42E-07
1421341_at Axin2 Mm.71710 1.930 up 3.41E-04 1.898 up 8.07E-05
1436826_at Tmtc3 Mm.296805 1.824 up 4.05E-04 2.548 up 1.35E-05
1433596_at Dnajc6 Mm.76494 1.816 up 5.75E-04 2.491 up 2.97E-06
1421492_at Ptgds2 Mm.442454 1.663 up 9.28E-05 2.135 up 8.43E-06
1433966_x_at Asns Mm.2942 1.634 up 3.88E-08 2.939 up 1.37E-05
1428748_at Zfp826 Mm.100056 1.583 up 4.01E-04 2.229 up 7.11E-05
1420549_at Gbp1 Mm.457978 1.534 up 5.81E-05 2.697 up 1.51E-06
1448595_a_at Bex1 Mm.422943 1.513 up 2.37E-06 2.557 up 1.63E-04
1442282_at Vmn2r84 Mm.359168 1.407 up 1.64E-06 2.165 up 2.75E-04
1433781_a_at Cldn12 Mm.40132 1.381 up 8.04E-05 2.766 up 3.81E-05
1420410_at Nr5a2 Mm.16794 1.373 up 7.95E-05 2.409 up 3.09E-05
1425964_x_at Hspb1 Mm.13849 1.365 up 1.30E-05 2.023 up 4.61E-04
1425454_a_at Il12a Mm.103783 1.346 up 7.81E-04 2.685 up 6.30E-07
1460603_at Samd9l Mm.196013 1.331 up 1.29E-05 2.187 up 1.12E-04
1433374_at Supt7l Mm.164187 1.319 up 1.53E-05 2.698 up 6.33E-05
1423626_at Dst Mm.336625 1.296 up 2.29E-04 2.292 up 5.73E-05
1449211_at Bpnt1 Mm.227549 1.294 up 5.63E-05 2.281 up 4.04E-06
1430744_at Napsa Mm.383181 1.290 up 2.75E-04 2.072 up 9.02E-07
1436865_at Slc26a11 Mm.31869 1.239 up 8.74E-06 2.549 up 3.95E-06
1457769_at H60a Mm.387042 1.234 up 1.01E-05 2.969 up 7.54E-06
1422873_at Prg2 Mm.142727 1.198 up 7.80E-04 2.471 up 1.67E-06
1455521_at Klf12 Mm.458816 1.163 up 5.93E-07 2.049 up 1.06E-06
1429366_at Lrrc34 Mm.45373 1.159 up 4.60E-04 2.309 up 1.19E-04
1455164_at Cdgap Mm.370848 1.158 up 1.03E-04 9.923 up 9.34E-07
1435203_at Man2a2 Mm.269245 1.142 up 2.19E-04 2.153 up 5.46E-05
1425521_at Paip1 Mm.132584 1.125 up 3.54E-05 3.036 up 1.04E-05
1424748_at Galnt11 Mm.425232 1.121 up 5.39E-05 2.129 up 5.17E-05
1430139_at Hells Mm.57223 1.103 up 1.41E-05 1.515 up 6.14E-05
1459253_at Arrdc3 Mm.423137 1.086 up 8.80E-06 3.616 up 3.11E-05
1452855_at Ly6k Mm.273319 1.080 up 2.75E-07 2.204 up 4.84E-05
1418872_at Abcb1b Mm.146649 1.075 up 5.07E-04 2.655 up 2.63E-05
1418148_at Abhd1 Mm.389615 1.060 up 7.17E-05 2.775 up 1.36E-05
1418645_at Hal Mm.13000 1.060 up 5.56E-06 2.599 up 8.49E-05
1438239_at Mid1 Mm.34441 1.049 up 2.41E-04 3.717 up 3.42E-06
1457936_at Mapk8 Mm.21495 1.016 up 4.56E-05 6.864 up 4.96E-05
1450897_at Arhgap5 Mm.35059 1.015 up 2.78E-05 2.256 up 2.14E-06
1426753_at Phf17 Mm.286285 1.008 up 1.68E-04 2.227 up 1.80E-06
1451704_at Abpd Mm.389857 17.022 down 2.60E-07 1.026 up 1.35E-05
1427380_at Klk1b3 Mm.439740 12.599 down 6.00E-07 1.002 up 3.08E-06
1420770_at Klk1b24 Mm.444308 10.713 down 6.26E-04 1.082 up 9.67E-08
1421587_at Klk1b27 Mm.445911 9.346 down 7.61E-07 1.019 up 9.93E-05
1419675_at Ngf Mm.1259 3.273 down 6.00E-04 1.003 up 7.25E-07
1433769_at Als2cl Mm.86338 3.143 down 2.89E-04 1.201 up 6.35E-05
1451637_a_at Muc10 Mm.200411 2.670 down 1.60E-07 1.658 up 9.91E-06
1448962_at Myh11 Mm.250705 2.391 down 2.05E-04 1.134 up 6.04E-04
1420700_s_at Folr4 Mm.86738 2.353 down 4.08E-04 1.097 up 1.39E-04
1453568_at Dapl1 Mm.275769 2.275 down 1.51E-05 1.351 up 8.10E-07
1449191_at Wfdc12 Mm.6433 2.190 down 3.29E-04 1.581 up 4.55E-06
1426044_a_at Prkcq Mm.329993 2.122 down 2.05E-05 1.038 up 1.17E-05
1418353_at Cd5 Mm.779 2.116 down 7.78E-05 1.197 up 1.71E-05
1416454_s_at Acta2 Mm.213025 2.046 down 9.14E-06 1.047 up 2.54E-06
1418612_at Slfn1 Mm.10948 2.028 down 1.92E-04 1.202 up 2.66E-05
1427532_at Trat1 Mm.167298 2.023 down 2.63E-04 1.344 up 3.91E-06
1446675_at Adk Mm.188734 1.527 down 5.26E-05 2.049 up 1.29E-05
1439843_at Camk4 Mm.222329 1.455 down 3.83E-05 2.411 up 2.24E-04
1417459_at Dcpp1 Mm.371556 1.359 down 4.85E-04 3.931 up 7.87E-06
1435462_at Plcxd2 Mm.380993 1.221 down 2.98E-06 11.585 up 1.09E-08
1425764_a_at Bcat2 Mm.24210 1.202 down 1.22E-04 2.147 up 5.28E-06
1431708_a_at Tia1 Mm.423551 1.149 down 1.10E-04 2.069 up 3.77E-05
1452406_x_at Erdr1 Mm.391385 1.129 down 3.51E-04 2.299 up 1.83E-05
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1436796_at Matr3 Mm.215034 1.128 down 2.35E-07 2.333 up 7.21E-05
1447517_at Skiv2l2 Mm.291029 1.107 down 7.18E-07 23.144 up 2.06E-05
1421628_at Il18r1 Mm.253664 1.074 down 2.17E-04 2.775 up 1.98E-08
1437308_s_at F2r Mm.24816 1.037 down 5.36E-05 3.819 up 1.08E-05
1420505_a_at Stxbp1 Mm.278865 1.037 down 3.03E-05 2.911 up 8.93E-05
1448712_at Chm Mm.257316 1.036 down 1.98E-05 2.772 up 3.83E-05
1450837_at Prp2 Mm.333439 2.478 up 2.44E-04 1.141 down 9.62E-04
1449153_at Mmp12 Mm.2055 2.386 up 3.71E-06 1.013 down 1.82E-04
1431035_at Daam1 Mm.87417 2.128 up 1.46E-04 2.076 down 1.52E-04
1429443_at Cpne4 Mm.326240 2.047 up 7.83E-05 1.055 down 5.16E-07
1450680_at Rag1 Mm.828 1.524 up 2.77E-04 3.785 down 2.66E-05
1439426_x_at Lyz1 Mm.177539 1.265 up 6.09E-04 2.372 down 5.72E-05
1419394_s_at S100a8 Mm.21567 1.129 up 1.25E-05 3.532 down 8.09E-06
1423547_at Lyz2 Mm.45436 1.126 up 8.46E-05 2.102 down 1.75E-05
1424339_at Oasl1 Mm.95479 1.090 up 4.93E-05 2.018 down 9.74E-06
1445305_at Slc10a7 Mm.334631 1.074 up 5.25E-05 2.014 down 6.07E-05
1448756_at S100a9 Mm.2128 1.073 up 8.26E-04 2.582 down 5.41E-04
1441228_at Apold1 Mm.296104 1.011 up 4.04E-06 2.082 down 5.97E-04
1452592_at Mgst2 Mm.24679 1.011 up 6.31E-05 2.763 down 7.82E-08
1420398_at Rgs18 Mm.253927 1.006 up 1.31E-06 2.893 down 1.62E-07
1453644_at Obp1a Mm.430771 57.487 down 3.72E-05 1.137 down 4.07E-05
1437432_a_at Trim12 Mm.458309 24.627 down 3.56E-05 1.012 down 8.10E-06
1421803_at Apbh Mm.6205 21.606 down 1.19E-04 1.043 down 1.09E-04
1419090_x_at Klk1b26 Mm.439663 11.300 down 3.47E-06 3.415 down 1.88E-04
1420490_at Klk1b16 Mm.440887 9.701 down 4.05E-04 1.279 down 2.57E-06
1425144_at Klk1b11 Mm.443378 9.173 down 2.09E-05 2.075 down 5.38E-05
1418093_a_at Egf Mm.252481 8.961 down 7.72E-05 1.401 down 2.55E-04
1420701_at Klk1b1 Mm.447819 8.958 down 6.41E-05 1.387 down 1.54E-07
1449313_at Klk1b5 Mm.443373 7.628 down 1.38E-05 2.216 down 1.62E-04
1451607_at Klk1b21 Mm.443292 7.373 down 1.31E-04 1.387 down 1.86E-04
1421372_at Klk1b4 Mm.440886 7.294 down 4.40E-05 1.251 down 2.88E-04
1449463_at Klk1b8 Mm.435488 7.244 down 3.78E-06 1.403 down 4.35E-05
1449838_at Crisp3 Mm.14138 6.279 down 6.35E-05 1.537 down 1.15E-07
1416325_at Crisp1 Mm.16781 6.068 down 5.28E-05 2.469 down 5.72E-05
1421490_at Prpmp5 Mm.441627 5.010 down 3.26E-06 3.225 down 7.50E-05
1424592_a_at Dnase1 Mm.440565 4.112 down 2.73E-05 1.889 down 1.73E-07
1424857_a_at Trim34 Mm.326945 4.070 down 8.92E-05 1.371 down 2.05E-05
1449447_at Cst10 Mm.117117 3.625 down 5.36E-05 1.834 down 2.33E-04
1419595_a_at Ggh Mm.20461 3.237 down 2.09E-04 2.913 down 1.56E-04
1416456_a_at Chia Mm.46418 3.116 down 8.13E-04 1.284 down 3.00E-05
1420492_s_at Smr3a Mm.431303 3.069 down 7.04E-08 1.528 down 2.05E-06
1454608_x_at Ttr Mm.2108 2.790 down 4.79E-05 1.348 down 1.78E-04
1453752_at Rpl17 Mm.276337 2.611 down 9.84E-05 1.210 down 1.98E-05
1448626_at Cdk5rap1 Mm.289427 2.573 down 1.05E-05 2.330 down 3.05E-06
1417023_a_at Fabp4 Mm.582 2.559 down 3.43E-04 1.474 down 4.62E-06
1448998_at Lpo Mm.41236 2.549 down 5.32E-05 1.173 down 4.46E-05
1428010_at Timm9 Mm.207767 2.522 down 1.05E-06 1.766 down 8.99E-05
1437614_x_at Zdhhc14 Mm.476811 2.379 down 6.32E-05 3.162 down 4.49E-06
1425505_at Mylk Mm.33360 2.375 down 2.91E-04 1.139 down 4.14E-04
1450136_at Cd38 Mm.249873 2.358 down 2.88E-07 2.442 down 3.85E-06
1449526_a_at Gdpd3 Mm.246881 2.284 down 1.95E-04 2.029 down 1.26E-04
1449212_at Pip Mm.214755 2.270 down 1.09E-04 1.128 down 6.60E-05
1417765_a_at Amy1 Mm.439727 2.245 down 2.86E-04 1.252 down 1.30E-04
1430465_at Raly Mm.221440 2.219 down 1.58E-04 1.884 down 1.92E-04
1444322_at Lcn11 Mm.27838 2.211 down 8.38E-07 1.421 down 2.29E-06
1423450_a_at Hs3st1 Mm.12559 2.128 down 3.87E-05 3.962 down 2.70E-05
1428402_at Zcchc3 Mm.427626 2.111 down 1.34E-04 2.168 down 2.70E-04
1440582_at Itch Mm.208286 2.090 down 2.37E-07 2.001 down 1.45E-07
1423110_at Col1a2 Mm.277792 2.078 down 2.26E-05 1.570 down 1.02E-04
1415837_at Klk1 Mm.142722 2.064 down 1.70E-04 2.372 down 1.67E-05
1423608_at Itm2a Mm.193 2.029 down 2.39E-04 1.322 down 1.36E-04
1419814_s_at S100a1 Mm.24662 2.020 down 6.75E-06 1.132 down 1.07E-04
1444416_at Cenpa Mm.290563 2.012 down 2.98E-06 11.798 down 4.69E-05
1419764_at Chi3l3 Mm.387173 1.822 down 2.85E-05 4.038 down 8.12E-06
1426278_at Ifi27 Mm.271275 1.703 down 7.11E-06 3.049 down 5.01E-06
1418967_a_at St7 Mm.12051 1.699 down 6.33E-06 4.363 down 1.72E-06
1428820_at Mapre1 Mm.143877 1.593 down 4.95E-07 2.286 down 3.13E-04
1450753_at Nkg7 Mm.34613 1.513 down 4.39E-06 2.205 down 4.58E-05
1436107_at Lsm8 Mm.275158 1.512 down 2.60E-05 5.470 down 5.19E-06
1457458_at Zc3h4 Mm.333594 1.489 down 5.68E-05 2.534 down 5.98E-04
1450883_a_at Cd36 Mm.18628 1.485 down 8.83E-05 2.425 down 9.15E-06
1426166_at Mup5 Mm.445286 1.472 down 2.42E-05 2.399 down 7.27E-06
1460241_a_at St3gal5 Mm.38248 1.435 down 2.00E-04 2.156 down 1.27E-04
1434572_at Hdac9 Mm.310551 1.431 down 1.33E-04 2.116 down 5.97E-07
1436485_s_at Whrn Mm.300397 1.384 down 1.30E-05 2.210 down 1.98E-06
1449015_at Retnla Mm.441868 1.344 down 1.93E-04 3.434 down 3.70E-05
1427306_at Ryr1 Mm.439745 1.336 down 8.50E-06 2.035 down 1.85E-07
1422824_s_at Eps8 Mm.235346 1.310 down 4.58E-05 2.085 down 2.20E-04
1449465_at Reln Mm.425236 1.300 down 6.19E-05 3.672 down 4.72E-05
1418722_at Ngp Mm.236225 1.296 down 3.99E-07 5.603 down 7.82E-08
1432026_a_at Herc5 Mm.297393 1.293 down 6.54E-04 2.016 down 2.20E-05
1424775_at Oas1a Mm.14301 1.279 down 1.17E-07 2.827 down 2.65E-05
1428490_at C1galt1 Mm.102752 1.264 down 1.88E-04 2.100 down 2.44E-06
1442107_at Flnb Mm.475646 1.251 down 2.09E-05 4.390 down 2.60E-04
1429359_s_at Rbpms Mm.323997 1.211 down 4.58E-05 2.334 down 1.31E-05
1453196_a_at Oasl2 Mm.228363 1.205 down 4.08E-06 2.012 down 2.48E-05
1455359_at Ptpn14 Mm.4498 1.204 down 5.86E-06 2.062 down 1.15E-06
1419691_at Camp Mm.3834 1.189 down 7.69E-07 2.971 down 3.10E-05
1437874_s_at Hexb Mm.27816 1.133 down 3.19E-04 2.373 down 2.70E-04
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1425908_at Gnb1 Mm.2344 1.122 down 4.27E-06 9.115 down 5.58E-05
1423555_a_at Ifi44 Mm.30756 1.032 down 2.29E-06 2.300 down 5.93E-05
*List of differentially expressed genes that distinguish between CD24+CD29+ salivary gland #""  cells of double mutant mice and CD24+CD29+ salivary gland cells 
")single mutant mice according to gene chip analysis. Affymetrix probe set ID (Probe ID), gene symbol (Symbol), Unigene ID, gene description, fold change (fc) and p-value 
(p) are shown. Grey-marked genes were specifically discussed in the text.
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Supplemental Table 5. Oligo sequences used for quantitative Real-Time PCR.  
Gene Primer sequence 
mc-myc forward 5’-TCCTGAAGCAGATCAGCAACAACC-3’ 
mc-myc reverse 5’-TGCTTGAATGGACAGGATGTAGGC-3’ 
mFas forward   5’-AGTGCAAACCAGACTTCTACTGCG-3’ 
mFas reverse 5’-AAGGATGGTCAACAACCATAGGCG-3’ 
mCK6 forward 5’-AGAGAGGGGTCGCATGAACT-3’ 
mCK6 reverse 5’-TCATCTGTTAGACTGTCTGCCTT-3’ 
mLoricrin forward 5’-TTGTGGAAAGACCTCTGGTGGAGG-3’ 
mLoricrin reverse 5’-AACCACCTCCATAGGAACCACCG-3`; 
mAxin2 forward 5’-AACTGAAACTGGAGCTGGAAAGCC-3’ 
mAxin2 reverse 5’-TTTGTGGGTCCTCTTCATAGCTGC-3’ 
mLef-1 forward 5’-TGATGCCCAATATGAACAGCGACC-3’ 
mLef-1 reverse 5’-TTGCTTGGAGTTGACATCTGACGG-3’ 
mBmp4 forward 5’-AGAAGAATAAGAACTGCCGTCGCC-3’ 
mBmp4 reverse 5’-ATGGCATGGTTGGTTGAGTTGAGG-3’ 
mMsx2 forward 5'-AAATCTGGTTCCAGAACCGAAGGG-3' 
mMsx2 reverse 5'-CATGGTAGATGCCATATCCAACCG-3' 
m-actin forward 5’-TCGTGCGTGACATCAAAGAGAAGC-3’ 
m-actin reverse 5’-ATGGATGCCACAGGATTCCATACC-3’ 
mDppa5 forward 5’-GAAATATCTGTTTGGCCCACAGGG-3’ 
mDppa5 reverse 5’-GCCATGGACTGAAGCATCCATTTAGC-3’ 
mDkk1 forward 5’-TGTTGTGCAAGACACTTCTGGTCC-3’ 
mDkk1 reverse 5’-TGTGGAGCCTAGAAGAATTGCTGG-3’ 
mNr5a2 forward 5’-ACACAGAAGTCGCGTTCAACAACC-3’ 
mNr5a2 reverse 5’-TAGTTGCAAACCGTGTAGTCCAGC-3’ 
mLrrc34 forward 5’-TCAAGGGAATAAACCTGAACCGGC-3’ 
mLrrc34 reverse 5’-ATTGCAGCTGACATCAAGGTAGCG-3’ 
mDnaja1 forward 5’-TACAGCTGGTTGAAGCATTGTGCG-3’ 
mDnaja1 reverse  5’-TCATATGGCCGACGGTATATTGGC-3’ 
mPdpn forward 5’-CACAGAGAACACGAGAGTACAACC-3’ 
mPdpn reverse 5’-ACGCCAACTATGATTCCAACCAGG-3’ 
mCdgap forward 5’-ATTGCCGGATTGGAAGAGAAAGCC-3’ 
mCdgap reverse 5’-ACGGTTGCTAAGTTCCAGTTGTGG-3’ 
mAbcb1b forward 5’-TTATGCTGCTTGTTTCCGGTTCGG-3’ 
mAbcb1b reverse 5’-TTTGGCTTTCGCATAGTCAGGAGC-3’ 
mGeminin forward 5’-ATCTCAGACTTCAAGCTGTGGTCC-3’ 
mGeminin reverse 5’-TTTATTCTCCTTTCTCAGGCGGGC-3’ 
mKlf5 forward 5’-ACGTCAATGAAACAGTTCCAGGGC-3’ 
mKlf5 reverse 5’-TTGGGTTGTGAATCGCCAGTTTGG-3’ 
mFgf5 forward 5’-TCCTTGCTCTTCCTCATCTTCTGC-3’ 
mFgf5 reverse 5’-ACTGGAAACTGCTATGTTCCGAGC-3’ 
mKlk1b3 forward 5’-ACCGATTTGTCAGCAAAGCCATCC-3’ 
mKlk1b3 reverse 5’-AATTTGGTGGGTGTAATGCTGCCC-3’ 
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mDnajc6 forward 5’-TCATTTGCCAGCAAACCTACCACC-3’ 
mDnajc6 reverse 5’-AAGCTCACGTTGTAATTGGGTCGG-3’ 
mKlf3 forward 5’-GAA GCC CAA CAA ATA TGG GGT-3’ 
mKlf3 reverse 5’-GGA CGG GAA CTT CAG AGA GG-3’ 
mTbx6 forward 5’-GGCAGCTCCATCTGTACCAT-3’ 
mTbx6 reverse 5’-ACCGAGGCTCAGTACATTGG-3’ 
mTrim2 forward 5’-TGGACAGTTCAAAAGTCGTTTCG-3’ 
mTrim2 reverse 5’-AATGCTAACCCACTTGTTGTCAT-3’ 
mCtnnb1 forward 5´-TGATTCGAAACCTTGCCCTTTGCC-3´ 
mCtnnb1 reverse 5´-TTACAATCCGGTTGTGAACGTCCC-3´ 
mMll1 forward 5´-AACAAGCATGGATCTCCCAATGCC-3´ 
mMll1 reverse 5´-ACATGTAGCAACCAATGCCCTTGC-3´ 
mCbp forward 5´-ACCACAAGTCCATTTGGACAACCC-3´ 
mCbp reverse 5´-TTCCCACTGATGTTTGCAACTGGG-3 
mAsh1 forward 5´-AGTTGAAGCTATGCAACGCCAAGC-3´ 
mAsh1 reverse 5´-TTCAATTCCGGGCTGACAAACTGG-3´ 
mAsh2 forward 5´-AAATGGTGTCAATCAGGGTGTGGC-3´ 
mAsh2 reverse 5´-ACATCAGCCAGTGTGTGTTCTACC-3´ 
mHells forward 5´-TTCGGAAATGTAATGGACAGC-3´ 
mHells reverse 5´-GGGCCACATACAAGAAAAGG-3´ 
mAmy1 forward 5´-ACATGTGGCCTGGAGACATAAAGG-3´ 
mAmy1 reverse 5´-ATCCCACTTGCGCATAACTTTGCC-3´ 
hNR5A2 forward 5’-TCATGGCCTATTTGCAGCAAGAGC-3’ 
hNR5A2 reverse 5’-ACCACTTGTCGGTAAATGTGGTCG-3’ 
hABCB1B forward   5’-AAGGCCTAATGCCGAACACATTGG-3’ 
h ABCB1B reverse 5’-TTTGCCATCAAGCAGCACTTTCCC-3’ 
hLRRC34 forward 5’-TAATGATATTGGGCCCGAAGGTGG-3’ 
hLRRC34 reverse 5’-TTGCATTCCCAGATCACAGTCACC-3’ 
hHELLS forward 5’-AAGGCATGGAATGGCTTAGGATGC-3’ 
hHELLS reverse 5’-CCAGTTAGGAAGTGTAGACAAAGGGC-3` 
hDNAJC6 forward 5’-ATCGAACTGCCAAGTTTCACAGCC-3’
hDNAJC6 reverse 5’-ACCAACCAGAATTGATGATGCCGC-3’ 
hMLL1 forward 5’-AGCAAGGTCATGGCAACAATCAGG-3’ 
hMLL1 reverse 5’-AGCTGCATTGGAAATCTGAGACGG-3’ 
hASH2 forward 5’-ATGGTTCACGGCTGACACATTTGG-3’ 
hASH2 reverse 5’-TTCGGATGTTCATCCTGTGTTCGG-3’ 
hAXIN2 forward 5'-TTCGGATGTTCATCCTGTGTTCGG-3' 
hAXIN2 reverse 5'-TGGTGCAAAGACATAGCCAGAACC-3' 
h-ACTIN forward 5’-TGGCACCACACCTTCTACAATGAGC-3’ 
h-ACTIN reverse 5’-GCACAGCTTCTCCTTAATGTCACGC-3’ 
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Supplemental Table 6. Oligonucleotide sequences used for transient RNAi.
Gene Oligo No. Target Sequence 
-catenin  
1 5’-GCUGAAACAUGCAGUUGUAUU-3´ 
2 5’-GAUAAAGGCUACUGUUGGAUU-3´ 
3 5’-CCACUAAUGUCCAGCGUUUUU-3´ 
4 5’-ACAAGUAGCUGAUAUUGAUUU-3´ 
Mll1 
1 5’-CGCCAAAUGGAGCGAGUUU-3´ 
2 5’-CCACCAAACCCACGAAGAA-3´ 
3 5’-AGACAAAGCCCUCGAAGGA-3´ 
4 5’-GCACAGUGGUCUCACGAUU-3´ 
Dppa5a 
1 5’-GUUACAUCCUAGCAAGAUA-3´ 
2 5’-AGUCGCUGGUGCUGAAAUA-3´ 
3 5’-CCACAGGGAUCUCGAAUGU-3´ 
4 5’-CGAAGAACUUAUCGAGGUC-3´ 
Crebbp 
(CBP) 
1 5’-GGACAGCUGUUUACCAUGA-3´ 
2 5’-GGAAUGAAGUCAAGGUUUG-3´ 
3 5’-GAAAGCAGCUGUGUACAAU-3´ 
4 5’-GCACAAGGAGGUAUUCUUU-3´ 
Ash1l 
1 5’-GCGAAACAAUGGACAAUUA-3´ 
2 5’-CAAGUAAGCUCGAGUCUGA-3´ 
3 5’-GCUUAAGUAUUGAGUGUAA-3´ 
4 5’-UAGUUGGACUGGUUAAUAA-3´ 
Control
1 5’-UGGUUUACAUGUCGACUAA-3´ 
2 5’-UGGUUUACAUGUUGUGUGA-3´ 
3 5’-UGGUUUACAUGUUUUCUGA-3´ 
4 5’-UGGUUUACAUGUUUUCCUA-3´ 
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Supplemental Table 7. Oligo sequences used for quantitative Real-Time PCR of ChIP samples.  
Gene Primer sequence Amplicon 
mMll1 forward_I 5'-ACATTCAATGGGAGAGTGCTTGCC-3' chr9:44692191+44692323 
mMll1 reverse_I 5'-AAAGAATCTCTCTCAGTGCCTCCC-3'  
mMll1 forward_II 5'-AGCGTCGCCCAATTGATTCTATGC-3' chr9:44689986+44690098 
mMll1 reverse_II 5'-AAAGAGCTCCAAGCGTGAAGATGG-3'  
mMll1 forward_III 5'-ACTGCCCTAGGAGTAACACATCTGC-3'  chr9:44688508+44688616 
mMll1 reverse_III 5'-TTCACAGATTACCTCATCCGAGCC-3'  
mMll1 forward_IV 5'-AGCACCAACTCCATGCAAGTAACC-3' chr9:44686793+44686890 
mMll1 reverse_IV 5'-TAAGCTGACAACACAGATCCCAGG-3'  
mHells forward_I 5'-AGCACCAGAATCAAAGGTGTGTGC-3' chr19:39003188+39003313 
mHells reverse_I 5'-TGTTGGCCTCCAACTCAGAAATCC-3'  
mHells forward_II 5'-ACCTACCGAAAGGACAGGTATTGG-3' chr19:39005106+39005195 
mHells reverse_II 5'-TAATGATGGTCCCGAGTTGTTCGG-3'  
mHells forward_III 5'-ACTTGAATCCCGTTCTGAAAGCCC-3' chr19:39005840+39005941
mHells reverse_III 5'-AGCATGGCTGGAGTAATCACCG-3'  
mHells forward_IV 5'-TGTGTGTGTGAGTGTGAGATGTCC-3' chr19:39007011+39007138 
mHells reverse_IV 5'-TGCAGAGGTACCAGGTTTGTTTCC-3'   
mAsh2 forward_I 5'-ATAGCCATCACTTCATGGCACAGG-3' chr8:26952740+26952888 
mAsh2 reverse_I 5'-ACGCAGAGATTGGTTAACTGTGGG-3'  
mAsh2 forward_II 5'-AAGCATATGGGTGGGCTCTAAACC-3' chr8:26951979+26952076 
mAsh2 reverse_II 5'-TACATGCGCACACATCCGTAAAGC-3'  
mAsh2 forward_III 5'-AAGCAAGACAAATGTGTTCGCGGC-3' chr8:26950689+26950787 
mAsh2 reverse_III 5'-CTTGCAATGCTTGGTCCTGAAAGC-3'
mAsh2 forward_IV 5'-AACAGCAGCATGGAAGTGTAAGCC-3' chr8:26948631+26948773 
mAsh2 reverse_IV 5'-ACCATAGCTAATGCAAGACCAGGG-3'  
mMyc forward 5'-TGCCCAGTCAACATAACTGTACGACC-3' chr15:61816229+61816317 
mMyc reverse 5'-AGAGCCACTTAGGGATAAACAGCC-3'  
mGapdh forward 5'-ACGGCGGTTCATTCATTTCCTTCC-3' chr6:125114819+125114915 
mGapdh reverse 5'-TGCATACCTTTGCGCATCATCTCC-3'  
hMLL1 forward_I 5'-TCTTCCTTCTTTCTGCTGCCTTGC-3' chr11:118304931+118305068
hMLL1 reverse_I 5'-TGTGTCAACAGATTTCTTCCCGCC-3'  
hMLL1 forward_II 5'-TTCGGGCTAACCCATCTTGTATCC-3' chr11:118306634+118306727 
hMLL1 reverse_II 5'-AGAGCAGCTTCCAGTATAACGCGG-3'  
hMLL1 forward_III 5'-ACCTCCTTTCCCTCTGAAGATAACGG-3' chr11:118309754+118309845
hMLL1 reverse_III 5'-AGAAACTGTAGCCCTGTAAGACGG-3'  
hMLL1 forward_IV 5'-CCATGTAGTTGGAGAACCAAAGGC-3' chr11:118309754+118309845 
hMLL1 reverse_IV 5'-CAACTCACATTTAAGCACCAACTCC-3'  
hHELLS forward_I 5'-TAACTATCCTGTGAGATTGGGCGAGG-3' chr10:96304154+96304293 
hHELLS reverse_I 5'-ATTAGCCTGGAATGGGCTAATGTCCG-3'  
hHELLS forward_II 5'-GGCGCCTTGCAAAGTATTAACAGC-3' chr10:96305252+96305370 
hHELLS reverse_II 5'-TAACTATCCTGTGAGATTGGGCGAGG-3'  
hHELLS forward_III 5'-GGGAGAAAGGCTGTTTCTTGTTGG-3' chr10:96306052+96306164 
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hHELLS reverse_III 5'-AGTTGTTCAACCATTGCTGGAGCC-3'  
hHELLS forward_IV 5'-TTGGGTGCCACAGTTGGTAAATGG-3' chr10:96307516+96307632 
hHELLS reverse_IV 5'-ACGGAAGGAGTATTACTGGAGTGG-3'  
hASH2 forward_I 5'-TAGAAGCAAGTCACTGAGTCCAGC-3' chr8:37960686+37960777 
hASH2 reverse_I 5'-GATTACAGGAGTGAGCCATCATGC-3'  
hASH2 forward_II 5'-ACCAGCTACTGTTGATGACTTCCC-3' chr8:37962357+37962438 
hASH2 reverse_II 5'-ATGTAGACAAGTTTGGTGCCCAGC-3'  
hASH2 forward_III 5'-AAGCTGCAGGAGTATGAAGTTCGG-3' chr8:37963787+37963923 
hASH2 reverse_III 5'-ACCGCTTACATCGACCAAGTTTGC-3'  
hASH2 forward_IV 5'-AATGGCAGGATCACAGCTTTCTGC-3' chr8:37965508+37965626 
hASH2 reverse_IV 5'-ATAAAGGAAAGCTGGGTGTGGTGG-3'  
hMYC forward 5'-GCGCCCATTAATACCCTTCTTTCC-3' chr8:128747818+128747989 
hMYC reverse 5'-ATAAATCATCGCAGGCGGAACAGC-3'  
hACTIN forward 5'-TGCAGAAAGTGCAAAGAACACGGC-3' chr7:5568420+5568576 
hACTIN reverse 5'-TGTGGGTGTAGGTACTAACACTGG-3'  
